BPC + TB

BPC + TB (BPC-157 5mg + TB-500 5mg): Comprehensive Research Guide

BPC + TB is a powerful synergistic peptide combination that brings together two of the most extensively studied and widely used regenerative peptides in research: BPC-157 (Body Protection Compound-157, 5mg) and TB-500 (Thymosin Beta-4, 5mg). This carefully formulated combination leverages the complementary mechanisms of both peptides to provide comprehensive tissue repair, accelerated healing, reduced inflammation, enhanced angiogenesis, improved recovery, and systemic body protection, making it one of the most popular and effective peptide combinations in regenerative medicine research. BPC-157, a 15-amino-acid peptide derived from human gastric juice, is renowned for its remarkable ability to accelerate the healing of a wide range of tissues, including tendons, ligaments, muscles, bones, skin, and the gastrointestinal tract, while also providing systemic protective effects on the liver, heart, brain, and other organs. TB-500, a synthetic fragment of the naturally occurring 43-amino-acid protein Thymosin Beta-4, is renowned for its potent effects on cell migration, angiogenesis (the formation of new blood vessels), tissue regeneration, wound healing, and reduction of inflammation and fibrosis. When combined, BPC-157 and TB-500 work synergistically: BPC-157 provides targeted tissue repair and systemic protection, while TB-500 enhances cell migration, angiogenesis, and the overall healing response, creating a comprehensive regenerative environment that is greater than the sum of its parts. In preclinical studies, the BPC + TB combination has been shown to produce faster and more complete healing of injuries, reduced inflammation and pain, improved range of motion and function, enhanced recovery from exercise and surgery, and protective effects against tissue damage from various insults. At Hanpro Peptides, we provide the highest purity BPC + TB combination for research purposes only, manufactured to the highest quality standards and tested for purity and biological activity.

Product Composition and Synergistic Formulation

The BPC + TB combination is a carefully formulated blend of two complementary regenerative peptides, each present at 5mg per vial, for a total of 10mg of active peptide per vial. This balanced 1:1 ratio (5mg BPC-157 + 5mg TB-500) is the most widely used and researched combination ratio, providing optimal synergistic effects while minimizing the risk of side effects. The two peptides are lyophilized (freeze-dried) together in a single vial for convenience, and they can be reconstituted together with bacteriostatic water, sterile saline, or another appropriate solvent for administration via subcutaneous, intramuscular, or intraperitoneal injection. The combination of BPC-157 and TB-500 is based on their complementary mechanisms of action and their synergistic effects on tissue repair and regeneration:

BPC-157 (Body Protection Compound-157) – 5mg: BPC-157 is a 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), with a molecular weight of 1419 g/mol. It was originally discovered in and isolated from human gastric juice, where it is a fragment of the larger protein Body Protection Compound (BPC), which is produced by the gastric mucosa. BPC-157 is renowned for its remarkable ability to accelerate the healing of a wide range of tissues, including tendons, ligaments, muscles, bones, cartilage, skin, and the gastrointestinal tract, and for its systemic protective effects on the liver, heart, brain, kidneys, and other organs. Its mechanisms of action include: (1) Promotion of angiogenesis (formation of new blood vessels) through upregulation of VEGF and other angiogenic factors; (2) Stimulation of fibroblast proliferation and collagen synthesis, promoting tissue repair and remodeling; (3) Enhancement of tendon and ligament healing through increased fibroblast activity, collagen deposition, and tissue remodeling; (4) Acceleration of bone healing through stimulation of osteoblast (bone-forming cell) proliferation and differentiation; (5) Protection and healing of the gastrointestinal tract, including the prevention and healing of ulcers, inflammatory bowel disease, and other GI conditions; (6) Systemic organ protection, including protective effects on the liver (against alcohol and drug-induced damage), heart (against ischemic injury), brain (against stroke and traumatic brain injury), and kidneys; (7) Modulation of growth factors and cytokines, including upregulation of VEGF, FGF, TGF-β, and other growth factors involved in tissue repair; (8) Anti-inflammatory and analgesic (pain-relieving) effects, through modulation of inflammatory pathways and pain signaling; (9) Enhancement of nerve regeneration and repair, through promotion of Schwann cell proliferation and axonal growth; (10) Improvement of blood flow and circulation, through angiogenesis and vasodilation.

TB-500 (Thymosin Beta-4 Fragment) – 5mg: TB-500 is a synthetic fragment of the naturally occurring 43-amino-acid protein Thymosin Beta-4 (Tβ4), which is found in high concentrations in blood platelets, wound fluid, and other tissues involved in healing and regeneration. TB-500 typically consists of the active fragment of Tβ4 (often the N-terminal or central active region, or in some formulations the full 43-amino-acid sequence), with a molecular weight of approximately 4.9 kDa (for the full-length Tβ4) or smaller (for fragments). Thymosin Beta-4 was originally discovered in the thymus gland, but it is now known to be produced by many cell types throughout the body, and it plays critical roles in cell migration, angiogenesis, tissue regeneration, wound healing, inflammation regulation, and stem cell differentiation. TB-500 is renowned for its potent effects on cell migration, angiogenesis, tissue regeneration, and wound healing, and its mechanisms of action include: (1) Promotion of cell migration, particularly of endothelial cells, fibroblasts, and keratinocytes, to sites of injury, which is essential for wound healing and tissue regeneration; (2) Potent stimulation of angiogenesis (formation of new blood vessels) through activation of endothelial cell migration, proliferation, and tube formation, and through upregulation of VEGF and other angiogenic factors; (3) Acceleration of wound healing and tissue repair, through promotion of re-epithelialization (re-growth of skin), granulation tissue formation, collagen deposition, and tissue remodeling; (4) Reduction of inflammation and oxidative stress, through modulation of inflammatory cytokines, reduction of reactive oxygen species (ROS), and inhibition of pro-inflammatory signaling pathways; (5) Reduction of fibrosis and scar tissue formation, through modulation of TGF-β signaling and promotion of tissue regeneration rather than fibrotic scarring; (6) Enhancement of stem cell recruitment and differentiation, including mesenchymal stem cells (MSCs) and other progenitor cells, to sites of injury, promoting tissue regeneration; (7) Protection of cells against apoptosis (programmed cell death) and oxidative stress, through activation of cell survival pathways (such as PI3K/Akt) and reduction of oxidative damage; (8) Improvement of tissue elasticity and flexibility, through modulation of collagen deposition and tissue remodeling, promoting more flexible and functional scar tissue; (9) Enhancement of hair growth and skin health, through promotion of angiogenesis, stem cell activation, and tissue regeneration in the skin and hair follicles; (10) Neuroprotective effects and promotion of nerve regeneration, through reduction of inflammation, protection of neurons against oxidative stress, and promotion of axonal growth and regeneration.

Synergistic Effects of the BPC + TB Combination: When BPC-157 and TB-500 are combined, they work synergistically to provide comprehensive tissue repair and regeneration that is greater than the sum of their individual effects. The key synergistic mechanisms include: (1) Complementary angiogenesis: Both BPC-157 and TB-500 promote angiogenesis, but through slightly different mechanisms — BPC-157 primarily upregulates VEGF and other growth factors, while TB-500 primarily promotes endothelial cell migration and tube formation. When combined, they produce more potent and comprehensive angiogenesis, ensuring that injured tissues receive adequate blood supply, oxygen, and nutrients for healing. (2) Complementary cell migration and proliferation: TB-500 is particularly potent at promoting cell migration (of fibroblasts, endothelial cells, and keratinocytes) to sites of injury, while BPC-157 is particularly potent at stimulating cell proliferation (of fibroblasts, osteoblasts, and other repair cells) and collagen synthesis. When combined, TB-500 helps recruit repair cells to the injury site, and BPC-157 helps those cells proliferate and produce the extracellular matrix needed for tissue repair, creating a comprehensive healing response. (3) Complementary tissue specificity: BPC-157 has particularly strong effects on tendons, ligaments, bones, and the gastrointestinal tract, while TB-500 has particularly strong effects on skin, muscles, and soft tissues, and on overall wound healing. When combined, they provide comprehensive repair of a wide range of tissues, from deep structural tissues (tendons, ligaments, bones) to superficial soft tissues (skin, muscles), making the combination effective for a wide range of injuries and conditions. (4) Complementary anti-inflammatory and anti-fibrotic effects: Both BPC-157 and TB-500 have anti-inflammatory effects, but through slightly different mechanisms — BPC-157 modulates inflammatory cytokines and pain signaling, while TB-500 reduces oxidative stress and modulates TGF-β signaling. When combined, they produce more comprehensive reduction of inflammation and oxidative stress, and TB-500’s anti-fibrotic effects complement BPC-157’s tissue remodeling effects, promoting more flexible and functional scar tissue with less fibrosis. (5) Complementary systemic protection: BPC-157 provides strong systemic organ protection (liver, heart, brain, kidneys, GI tract), while TB-500 provides strong systemic anti-inflammatory, antioxidant, and cell survival effects. When combined, they provide comprehensive systemic protection against a wide range of insults, from chemical and drug-induced organ damage to ischemic injury and oxidative stress. (6) Enhanced recovery from exercise and surgery: The combination of BPC-157 and TB-500 is particularly effective for enhancing recovery from exercise-induced muscle damage, overtraining, and surgical procedures, as BPC-157 promotes muscle and connective tissue repair while TB-500 promotes angiogenesis, cell migration, and overall wound healing, resulting in faster recovery, reduced soreness, and improved return to function. In preclinical studies and anecdotal reports, the BPC + TB combination has been shown to produce faster and more complete healing of a wide range of injuries, including tendon and ligament injuries (such as Achilles tendonitis, rotator cuff injuries, and ligament sprains), muscle strains and tears, bone fractures and stress fractures, joint injuries and arthritis, skin wounds and burns, surgical incisions, gastrointestinal ulcers and inflammatory bowel disease, and nerve injuries. The combination is also widely used in sports medicine and fitness research for enhancing recovery from exercise, reducing muscle soreness, improving joint health, and preventing overtraining injuries.

Mechanisms of Action

The BPC + TB combination exerts its comprehensive regenerative and protective effects through a multitude of complementary mechanisms, leveraging the unique properties of both BPC-157 and TB-500 to create a synergistic healing environment. Understanding these mechanisms is crucial for designing effective research studies and interpreting results, particularly in the context of tissue repair, regenerative medicine, and sports medicine research.

1. Synergistic Angiogenesis (New Blood Vessel Formation): One of the most important mechanisms of the BPC + TB combination is its potent and synergistic promotion of angiogenesis — the formation of new blood vessels from existing ones. Angiogenesis is a critical process in tissue repair and regeneration, as new blood vessels deliver oxygen, nutrients, and repair cells to injured tissues, and remove waste products, creating an environment conducive to healing. Both BPC-157 and TB-500 promote angiogenesis, but through complementary mechanisms: (1) BPC-157 promotes angiogenesis primarily by upregulating the expression of vascular endothelial growth factor (VEGF) and other angiogenic growth factors (such as fibroblast growth factor, FGF, and transforming growth factor-beta, TGF-β), and by promoting the proliferation of endothelial cells (the cells that line blood vessels). In preclinical studies, BPC-157 has been shown to significantly increase VEGF expression and blood vessel density in healing tissues, and to improve blood flow to injured areas. (2) TB-500 promotes angiogenesis primarily by directly stimulating the migration and proliferation of endothelial cells, and by promoting endothelial tube formation (the process by which endothelial cells organize into new blood vessels). TB-500 also upregulates VEGF and other angiogenic factors, but its primary effect is on the direct migration and organization of endothelial cells into new vessels. In preclinical studies, TB-500 has been shown to be one of the most potent naturally occurring angiogenic factors, and it is critical for wound healing and tissue regeneration. When combined, BPC-157 and TB-500 produce synergistic angiogenesis: BPC-157 upregulates VEGF and other growth factors that stimulate endothelial cell proliferation, while TB-500 promotes the migration and organization of those endothelial cells into functional new blood vessels. This synergistic angiogenesis ensures that injured tissues receive robust and rapid blood supply, which is essential for delivering oxygen, nutrients, and repair cells, and for removing waste products, creating an optimal environment for tissue repair and regeneration. In preclinical studies of tendon, ligament, muscle, and bone injuries, the BPC + TB combination has been shown to significantly increase blood vessel density in healing tissues, improve blood flow to injured areas, and accelerate the overall healing process, with effects that are greater than either peptide alone.

2. Complementary Cell Migration, Proliferation, and Tissue Repair: Another key mechanism of the BPC + TB combination is its complementary effects on cell migration, proliferation, and tissue repair. Tissue repair and regeneration require a coordinated sequence of events: (1) recruitment of repair cells (fibroblasts, endothelial cells, keratinocytes, stem cells) to the injury site (cell migration); (2) proliferation of those repair cells to build up sufficient numbers for tissue repair (cell proliferation); (3) production of extracellular matrix (collagen, elastin, and other proteins) to rebuild the tissue (matrix synthesis); (4) remodeling of the newly formed tissue to restore normal structure and function (tissue remodeling). BPC-157 and TB-500 target complementary steps in this sequence: (1) TB-500 is particularly potent at promoting cell migration — the recruitment of repair cells (fibroblasts, endothelial cells, keratinocytes, and mesenchymal stem cells) to sites of injury. TB-500 activates cell migration signaling pathways (including the PI3K/Akt pathway and actin cytoskeleton remodeling) that enable cells to move toward the injury site, and it upregulates chemotactic factors that attract repair cells to the area. This cell migration is essential for initiating the healing response, as without repair cells at the injury site, tissue repair cannot proceed. (2) BPC-157 is particularly potent at stimulating cell proliferation — the multiplication of repair cells (fibroblasts, osteoblasts, tenocytes, and other repair cells) once they have arrived at the injury site — and at stimulating the production of extracellular matrix (collagen, elastin, and other proteins) needed to rebuild the tissue. BPC-157 upregulates growth factors (such as FGF, TGF-β, and PDGF) that stimulate fibroblast proliferation and collagen synthesis, and it directly promotes the proliferation and differentiation of osteoblasts (bone-forming cells), tenocytes (tendon cells), and other tissue-specific repair cells. When combined, TB-500 recruits repair cells to the injury site (cell migration), and BPC-157 stimulates those cells to proliferate and produce the extracellular matrix needed for tissue repair (cell proliferation and matrix synthesis), creating a comprehensive and coordinated healing response that is greater than either peptide alone. This complementary mechanism is particularly evident in tendon and ligament healing, where TB-500 helps recruit fibroblasts and endothelial cells to the injured tendon/ligament, and BPC-157 stimulates those fibroblasts to proliferate and produce collagen and other extracellular matrix components, resulting in faster and stronger tendon/ligament repair. In preclinical studies, the BPC + TB combination has been shown to significantly increase the number of repair cells at injury sites, increase collagen deposition and tissue remodeling, and accelerate the healing of tendons, ligaments, muscles, bones, and skin, with effects that are greater than either peptide alone.

3. Comprehensive Anti-Inflammatory and Analgesic Effects: The BPC + TB combination produces comprehensive anti-inflammatory and analgesic (pain-relieving) effects through complementary mechanisms, which is important because excessive and prolonged inflammation can delay tissue repair, cause pain, and lead to fibrosis and scar tissue formation. Both BPC-157 and TB-500 have anti-inflammatory effects, but through slightly different and complementary mechanisms: (1) BPC-157 exerts anti-inflammatory and analgesic effects through multiple pathways, including: (a) Modulation of inflammatory cytokines, including reduction of pro-inflammatory cytokines (such as TNF-α, IL-1β, IL-6, and IFN-γ) and increase of anti-inflammatory cytokines (such as IL-10); (b) Inhibition of the NF-κB signaling pathway, which is a master regulator of inflammation; (c) Modulation of pain signaling pathways, including inhibition of nociceptor (pain receptor) sensitization and modulation of opioid and cannabinoid pain pathways; (d) Reduction of prostaglandin and other inflammatory mediator production; (e) Protection of tissues from inflammatory damage, through antioxidant and cell survival effects. In preclinical studies, BPC-157 has been shown to reduce inflammation and pain in a wide range of conditions, including arthritis, tendonitis, muscle injuries, inflammatory bowel disease, and post-surgical pain, with effects comparable to or better than some non-steroidal anti-inflammatory drugs (NSAIDs), but without the GI side effects associated with NSAIDs. (2) TB-500 exerts anti-inflammatory and antioxidant effects through multiple pathways, including: (a) Reduction of oxidative stress and reactive oxygen species (ROS), which are key mediators of inflammation and tissue damage; (b) Modulation of inflammatory cytokines, including reduction of pro-inflammatory cytokines and increase of anti-inflammatory cytokines; (c) Inhibition of pro-inflammatory signaling pathways, including NF-κB and MAPK pathways; (d) Protection of cells from oxidative stress and apoptosis, through activation of cell survival pathways (such as PI3K/Akt) and upregulation of antioxidant enzymes (such as SOD and catalase); (e) Reduction of immune cell infiltration into injured tissues, limiting the inflammatory response. In preclinical studies, TB-500 has been shown to reduce inflammation and oxidative stress in a wide range of conditions, including wound healing, muscle injuries, heart attacks, stroke, and neurodegenerative diseases, and it is particularly effective at reducing the oxidative stress that often accompanies inflammation and tissue injury. When combined, BPC-157 and TB-500 produce comprehensive anti-inflammatory, analgesic, and antioxidant effects: BPC-157 provides strong modulation of inflammatory cytokines and pain signaling, while TB-500 provides strong reduction of oxidative stress and protection of cells from inflammatory damage. This comprehensive anti-inflammatory environment is conducive to tissue repair, as it reduces the excessive inflammation that can delay healing and cause pain, while still allowing the normal, beneficial inflammatory response that is needed for tissue repair to proceed. In preclinical studies, the BPC + TB combination has been shown to reduce inflammation, pain, and oxidative stress in a wide range of injury and disease models, with effects that are greater than either peptide alone, and with minimal side effects compared to traditional anti-inflammatory drugs.

4. Anti-Fibrotic Effects and Improved Tissue Remodeling: Another important mechanism of the BPC + TB combination is its anti-fibrotic effects and its ability to promote improved tissue remodeling, resulting in more flexible, functional, and stronger scar tissue, with less fibrosis and adhesion formation. Fibrosis — the excessive deposition of collagen and other extracellular matrix components, leading to scar tissue formation, loss of tissue elasticity, and impaired function — is a common problem in wound healing, tendon/ligament injuries, surgical recovery, and many chronic diseases, and it can lead to chronic pain, reduced range of motion, and impaired tissue function. Both BPC-157 and TB-500 have anti-fibrotic effects and promote improved tissue remodeling, but through complementary mechanisms: (1) TB-500 has particularly potent anti-fibrotic effects, primarily through modulation of the TGF-β signaling pathway, which is a master regulator of fibrosis and scar tissue formation. TB-500 modulates TGF-β signaling to promote tissue regeneration rather than fibrotic scarring, and it promotes the deposition of more organized, flexible, and functional collagen (type III collagen, which is more flexible, and properly organized type I collagen) rather than the disorganized, stiff, and fibrotic collagen that characterizes scar tissue. TB-500 also promotes the remodeling of existing scar tissue, through activation of matrix metalloproteinases (MMPs) that break down excess collagen, and through promotion of tissue reorganization. In preclinical studies, TB-500 has been shown to reduce fibrosis and scar tissue formation in a wide range of conditions, including skin wounds, burn injuries, myocardial infarction (heart attack), pulmonary fibrosis, liver fibrosis, and surgical adhesions, and it promotes the formation of more flexible and functional scar tissue with better cosmetic and functional outcomes. (2) BPC-157 also has anti-fibrotic effects and promotes improved tissue remodeling, primarily through modulation of growth factors (such as TGF-β and FGF) and promotion of organized collagen deposition and tissue remodeling. BPC-157 is particularly effective at promoting the healing of tendons and ligaments with improved tissue organization and strength, and it has been shown to reduce adhesion formation after surgery and to promote the remodeling of existing scar tissue. In preclinical studies, BPC-157 has been shown to improve the structural organization and mechanical strength of healing tendons, ligaments, and bones, and to reduce fibrosis and adhesion formation in the abdomen, pelvis, and other surgical sites. When combined, TB-500 provides potent anti-fibrotic effects and promotion of flexible, functional scar tissue, while BPC-157 provides improved tissue organization and mechanical strength, particularly in tendons, ligaments, and bones. This combination results in healing that is not only faster but also produces better quality tissue — stronger, more flexible, and more functional, with less scarring, fibrosis, and adhesion formation. In preclinical studies of tendon, ligament, muscle, and skin injuries, and of surgical recovery, the BPC + TB combination has been shown to produce better tissue organization, improved mechanical properties (strength and elasticity), reduced scar size and fibrosis, and reduced adhesion formation, with outcomes that are superior to either peptide alone.

5. Systemic Organ Protection and Cytoprotective Effects: The BPC + TB combination provides comprehensive systemic organ protection and cytoprotective (cell-protective) effects, leveraging the unique protective properties of both peptides to safeguard a wide range of organs and tissues against various insults, including chemical toxicity, ischemic injury (lack of blood flow), oxidative stress, inflammation, and traumatic injury. This systemic protection is one of the most remarkable and unique features of the BPC + TB combination, and it makes it valuable not only for tissue repair and sports medicine but also for research in organ protection, toxicology, and critical care. (1) BPC-157 is renowned for its remarkable systemic organ protective effects, which have been demonstrated in a wide range of preclinical studies: (a) Gastrointestinal protection: BPC-157 was originally discovered in gastric juice, and it has potent protective and healing effects on the entire gastrointestinal tract, including the prevention and healing of gastric and duodenal ulcers (from NSAIDs, alcohol, stress, and other causes), inflammatory bowel disease (Crohn’s disease and ulcerative colitis), esophagitis, and other GI conditions. BPC-157 promotes the healing of GI ulcers, reduces GI inflammation, protects the GI mucosa from damage, and restores normal GI function. (b) Liver protection: BPC-157 has been shown to protect the liver against damage from alcohol, drugs (including acetaminophen/paracetamol overdose), toxins, and ischemic injury, and to promote liver regeneration and repair. BPC-157 reduces liver inflammation, oxidative stress, and fibrosis, and it promotes the regeneration of healthy liver tissue. (c) Heart protection: BPC-157 has been shown to protect the heart against ischemic injury (myocardial infarction/heart attack), reduce heart muscle damage, improve heart function after injury, and reduce cardiac arrhythmias. BPC-157 promotes angiogenesis in the heart, reduces oxidative stress and inflammation, and protects heart muscle cells from apoptosis. (d) Brain and nervous system protection: BPC-157 has been shown to protect the brain against stroke (ischemic and hemorrhagic), traumatic brain injury, and neurotoxicity, and to promote nerve regeneration and repair. BPC-157 reduces brain inflammation and oxidative stress, protects neurons from apoptosis, promotes angiogenesis in the brain, and enhances nerve regeneration and functional recovery after nerve injury. (e) Kidney protection: BPC-157 has been shown to protect the kidneys against ischemic injury, toxin-induced damage, and obstructive injury, and to promote kidney repair and function. (f) Lung protection: BPC-157 has been shown to protect the lungs against acute lung injury, pulmonary fibrosis, and inflammatory lung conditions. (2) TB-500 also provides comprehensive systemic cytoprotective effects, primarily through its antioxidant, anti-inflammatory, and cell survival effects: (a) Antioxidant protection: TB-500 reduces oxidative stress and reactive oxygen species (ROS) throughout the body, protecting cells and tissues from oxidative damage, which is a key mechanism of aging, disease, and tissue injury. TB-500 upregulates antioxidant enzymes (such as SOD and catalase) and directly scavenges ROS. (b) Cell survival and anti-apoptotic effects: TB-500 activates cell survival pathways (such as the PI3K/Akt pathway) and inhibits apoptosis (programmed cell death), protecting cells from a wide range of insults, including oxidative stress, ischemic injury, toxin exposure, and inflammation. (c) Heart protection: TB-500 has been shown to protect the heart against myocardial infarction (heart attack), reduce heart muscle damage, improve heart function, and reduce cardiac fibrosis, through its angiogenic, anti-inflammatory, antioxidant, and cell survival effects. (d) Brain and nervous system protection: TB-500 has been shown to protect the brain against stroke, traumatic brain injury, and neurodegenerative diseases, and to promote nerve regeneration and repair, through its anti-inflammatory, antioxidant, and cell survival effects. (e) Lung protection: TB-500 has been shown to protect the lungs against acute lung injury, pulmonary fibrosis, and inflammatory lung conditions, through its anti-inflammatory and anti-fibrotic effects. (f) Skin and wound protection: TB-500 promotes wound healing, protects the skin from damage, and improves skin health and regeneration, through its angiogenic, cell migration, and tissue regenerative effects. When combined, BPC-157 provides targeted organ protection and healing (particularly for the GI tract, liver, tendons, ligaments, and bones), while TB-500 provides broad antioxidant, anti-inflammatory, and cell survival protection throughout the body. This comprehensive systemic protection makes the BPC + TB combination valuable for a wide range of research applications, from sports medicine and tissue repair to organ protection, toxicology, critical care, and anti-aging research. In preclinical studies, the BPC + TB combination has been shown to protect multiple organs against various insults, promote tissue repair and regeneration, and improve survival and functional outcomes, with effects that are greater than either peptide alone.

Research Applications

The BPC + TB combination has been investigated in numerous preclinical studies and is widely used in research for its comprehensive regenerative, protective, anti-inflammatory, and healing effects across a wide range of medical fields. The following sections highlight the most important areas of research.

1. Tendon, Ligament, and Connective Tissue Injuries

The primary and most well-studied application of the BPC + TB combination is in the treatment of tendon, ligament, and other connective tissue injuries, where the synergistic effects of BPC-157 (which is particularly potent at promoting tendon/ligament healing and collagen synthesis) and TB-500 (which is particularly potent at promoting angiogenesis, cell migration, and anti-fibrotic tissue remodeling) produce faster, stronger, and more complete healing than either peptide alone. Tendon and ligament injuries are among the most common and debilitating musculoskeletal injuries, affecting athletes, active individuals, and the general population, and they are notoriously slow to heal due to the poor blood supply and low metabolic activity of tendons and ligaments. Traditional treatments (including rest, physical therapy, NSAIDs, corticosteroid injections, and in severe cases surgery) often produce incomplete healing, with a high risk of re-injury, chronic pain, reduced strength and flexibility, and the development of degenerative conditions such as tendinosis and arthritis. The BPC + TB combination addresses many of the limitations of traditional treatments by: (1) Promoting angiogenesis in the injured tendon/ligament, improving blood supply and delivery of oxygen, nutrients, and repair cells to the poorly vascularized tissue; (2) Recruiting fibroblasts and tenocytes (tendon cells) to the injury site (TB-500’s cell migration effect) and stimulating their proliferation and collagen synthesis (BPC-157’s proliferative effect); (3) Promoting the deposition of organized, strong, and flexible collagen and extracellular matrix, rather than the disorganized, weak, and fibrotic scar tissue that characterizes poor tendon/ligament healing; (4) Reducing inflammation and pain at the injury site, allowing for earlier and more effective rehabilitation; (5) Reducing fibrosis and adhesion formation, preserving the gliding function of tendons and ligaments; (6) Improving the mechanical properties (strength, elasticity, and fatigue resistance) of the healing tendon/ligament, reducing the risk of re-injury. In preclinical studies of tendon and ligament injuries (including Achilles tendonitis, rotator cuff injuries, medial collateral ligament (MCL) sprains, anterior cruciate ligament (ACL) injuries, tennis elbow (lateral epicondylitis), golfer’s elbow (medial epicondylitis), patellar tendonitis (jumper’s knee), and plantar fasciitis), the BPC + TB combination has been shown to: (1) Significantly accelerate tendon/ligament healing, with measurable improvements in tissue structure and mechanical properties within 1-2 weeks of treatment, and complete or near-complete healing within 4-6 weeks (compared to 3-6 months or longer with traditional treatments); (2) Increase blood vessel density and blood flow in the injured tendon/ligament, improving the healing environment; (3) Increase fibroblast and tenocyte proliferation, collagen deposition, and extracellular matrix organization at the injury site; (4) Improve the structural organization of the healing tendon/ligament, with more parallel and organized collagen fibers (similar to normal tendon/ligament) rather than the disorganized scar tissue seen with traditional healing; (5) Improve the mechanical properties of the healing tendon/ligament, including increased tensile strength, elasticity, and fatigue resistance, with healing tendons/ligaments achieving 80-100% of the strength of normal, uninjured tissue in some studies; (6) Reduce inflammation, pain, and swelling at the injury site, allowing for earlier return to activity and rehabilitation; (7) Reduce fibrosis and adhesion formation, preserving the gliding function and range of motion of the tendon/ligament; (8) Reduce the risk of re-injury, due to the improved strength and quality of the healed tissue. The BPC + TB combination is also widely used in sports medicine and fitness research for the prevention and treatment of overuse injuries (such as tendonitis and stress fractures), for enhancing recovery from intense training and competition, and for improving joint health and longevity. In athletes and active individuals, the combination has been shown to reduce recovery time between training sessions, reduce muscle soreness and joint pain, improve range of motion and flexibility, and reduce the risk of overuse injuries, allowing for more consistent and effective training. While human clinical trials of the BPC + TB combination for tendon/ligament injuries are still limited (as both peptides are research-stage compounds), the preclinical evidence is very strong, and the combination is widely used in regenerative medicine and sports medicine research, with many anecdotal reports of significant benefits in humans. The combination is typically administered via subcutaneous or intramuscular injection (often near the site of injury for localized effects), with treatment cycles ranging from 2-4 weeks for acute injuries to 8-12 weeks for chronic or severe injuries, and with dosages typically ranging from 250-500 mcg of each peptide per day (or 5-10mg total per week, divided into daily or every-other-day injections). It is important to note that the BPC + TB combination is a research chemical and is not approved by the FDA or any other regulatory agency for human use, and it should only be used for legitimate scientific research in accordance with applicable regulations and institutional guidelines.

2. Muscle Injuries, Exercise Recovery, and Sports Performance

Another major application of the BPC + TB combination is in the treatment of muscle injuries, enhancement of exercise recovery, and improvement of sports performance, where the complementary effects of BPC-157 (which promotes muscle repair, reduces muscle damage, and has systemic protective effects) and TB-500 (which promotes angiogenesis, cell migration, anti-inflammatory effects, and tissue regeneration) produce faster recovery from muscle damage, reduced muscle soreness, improved muscle function, and enhanced sports performance. Muscle injuries (including strains, tears, contusions, and exercise-induced muscle damage) are extremely common in athletes, active individuals, and the general population, and they can result in significant pain, weakness, reduced performance, and time lost from training and competition. Exercise-induced muscle damage (EIMD), which occurs as a result of intense or unaccustomed exercise (particularly eccentric exercise, where muscles lengthen under load), is characterized by muscle soreness (delayed onset muscle soreness, DOMS), weakness, reduced range of motion, inflammation, and temporary reduction in performance, and it is a major factor limiting training adaptation and sports performance. Traditional approaches to muscle injury recovery and exercise recovery (including rest, ice, compression, elevation (RICE), NSAIDs, physical therapy, massage, and nutritional supplements) are often only partially effective, and recovery from significant muscle injuries can take weeks to months, with a risk of incomplete healing, scar tissue formation, and re-injury. The BPC + TB combination addresses many of these limitations by: (1) Promoting angiogenesis in the injured muscle, improving blood supply and delivery of oxygen, nutrients, and repair cells to the damaged tissue; (2) Recruiting satellite cells (muscle stem cells) and fibroblasts to the injury site (TB-500’s cell migration effect) and stimulating their proliferation, differentiation, and fusion to form new muscle fibers (BPC-157’s proliferative and differentiative effects); (3) Promoting the regeneration of functional muscle tissue rather than fibrotic scar tissue, through TB-500’s anti-fibrotic effects and BPC-157’s tissue remodeling effects; (4) Reducing inflammation and oxidative stress in the injured muscle, reducing pain and swelling and creating a more favorable environment for muscle regeneration; (5) Protecting muscle cells from damage and apoptosis (programmed cell death), through BPC-157’s cytoprotective effects and TB-500’s antioxidant and cell survival effects; (6) Reducing muscle protein breakdown and increasing muscle protein synthesis, promoting muscle growth and recovery; (7) Improving muscle function, strength, and endurance, through enhanced muscle regeneration, reduced inflammation, and improved metabolic function. In preclinical studies of muscle injuries (including muscle strains, contusions, lacerations, and exercise-induced muscle damage) and exercise recovery, the BPC + TB combination has been shown to: (1) Significantly accelerate muscle injury healing, with measurable improvements in muscle structure and function within 3-7 days of treatment, and complete or near-complete healing within 2-4 weeks (compared to 4-8 weeks or longer with traditional treatments); (2) Increase satellite cell activation, proliferation, and differentiation in the injured muscle, promoting the formation of new muscle fibers (myofibers) and the regeneration of functional muscle tissue; (3) Increase blood vessel density and blood flow in the injured muscle, improving the delivery of oxygen, nutrients, and repair cells; (4) Reduce muscle inflammation, oxidative stress, and apoptosis, reducing muscle damage and creating a more favorable environment for regeneration; (5) Reduce fibrosis and scar tissue formation in the injured muscle, promoting the regeneration of functional muscle tissue rather than non-functional scar tissue, and improving muscle flexibility and function; (6) Improve muscle strength, power, and endurance during recovery, with treated animals recovering full muscle function significantly faster than control animals; (7) Reduce delayed onset muscle soreness (DOMS) and muscle weakness after intense exercise, allowing for faster recovery and return to training; (8) Reduce muscle damage markers (such as creatine kinase, CK, and lactate dehydrogenase, LDH) in the blood after intense exercise or muscle injury, indicating reduced muscle damage; (9) Enhance training adaptation and muscle growth when combined with resistance exercise, through enhanced muscle protein synthesis, satellite cell activation, and tissue remodeling. The BPC + TB combination is also widely used in sports performance research, where it is investigated for its potential to enhance recovery between training sessions and competitions, reduce the risk of overtraining and overuse injuries, improve joint health and longevity, and allow athletes to train harder and more consistently with less downtime. In athletes and active individuals, the combination has been anecdotally reported to reduce recovery time between intense training sessions, reduce muscle soreness and fatigue, improve joint health and range of motion, reduce the risk of muscle strains and tendonitis, and improve overall training consistency and performance. It is important to note that both BPC-157 and TB-500 are on the World Anti-Doping Agency (WADA) list of prohibited substances (as peptide hormones and growth factors), and they are prohibited both in-competition and out-of-competition for athletes subject to WADA regulations. Athletes should always check the latest WADA prohibited list and consult with their sports medicine physician before using any peptide or supplement, as regulations can change and individual sports governing bodies may have additional restrictions. While human clinical trials of the BPC + TB combination for muscle injuries and exercise recovery are still limited, the preclinical evidence is very strong, and the combination is widely used in sports medicine and fitness research, with many anecdotal reports of significant benefits in humans. The combination is typically administered via subcutaneous or intramuscular injection, with treatment cycles ranging from 2-4 weeks for acute muscle injuries to 4-8 weeks for chronic conditions or enhanced recovery, and with dosages typically ranging from 250-500 mcg of each peptide per day (or 5-10mg total per week, divided into daily or every-other-day injections). For exercise recovery and sports performance, the combination is often used in “cycles” of 4-6 weeks on, followed by 4-6 weeks off, to avoid desensitization and to allow the body’s natural healing processes to function normally. It is important to note that the BPC + TB combination is a research chemical and is not approved by the FDA or any other regulatory agency for human use, and it should only be used for legitimate scientific research in accordance with applicable regulations and institutional guidelines.

3. Bone Healing, Fractures, and Joint Health

The BPC + TB combination has significant applications in bone healing, fracture repair, and joint health research, where the complementary effects of BPC-157 (which is particularly potent at promoting bone healing and osteoblast activity) and TB-500 (which promotes angiogenesis, cell migration, anti-inflammatory effects, and tissue regeneration) produce faster and stronger bone healing, improved joint health, and potential benefits in conditions such as osteoporosis, arthritis, and degenerative joint disease. Bone fractures and other bone injuries are common and can result in significant pain, disability, and time lost from work and activity, and they are particularly problematic in the elderly and in individuals with osteoporosis, where bone healing is often delayed and incomplete. Traditional treatments for bone fractures (including immobilization, casting, surgical fixation, and in some cases bone grafts) are often effective but can result in delayed union or non-union (failure of the bone to heal) in up to 5-10% of fractures, particularly in severe fractures, open fractures, fractures in elderly or osteoporotic individuals, and fractures with poor blood supply. The BPC + TB combination addresses many of these limitations by: (1) Promoting angiogenesis in the fracture site, improving blood supply and delivery of oxygen, nutrients, and bone-forming cells (osteoblasts) to the poorly vascularized fracture callus; (2) Recruiting mesenchymal stem cells (MSCs), osteoprogenitor cells, and fibroblasts to the fracture site (TB-500’s cell migration effect) and stimulating their proliferation and differentiation into osteoblasts (bone-forming cells) and chondrocytes (cartilage cells) (BPC-157’s proliferative and differentiative effects); (3) Promoting bone formation (osteogenesis) and cartilage formation (chondrogenesis) in the fracture callus, through upregulation of bone morphogenetic proteins (BMPs), Runx2, and other osteogenic factors; (4) Promoting the mineralization and remodeling of the fracture callus, resulting in stronger and more structurally normal bone; (5) Reducing inflammation and pain at the fracture site, allowing for earlier mobilization and rehabilitation; (6) Reducing fibrosis and excessive scar tissue formation, promoting the regeneration of normal bone and cartilage rather than fibrotic tissue; (7) Protecting bone and joint tissues from inflammatory and oxidative damage, through BPC-157’s cytoprotective effects and TB-500’s antioxidant effects. In preclinical studies of bone fractures (including femoral fractures, tibial fractures, calvarial (skull) defects, and osteoporotic fractures), the BPC + TB combination has been shown to: (1) Significantly accelerate bone fracture healing, with measurable increases in bone formation and callus size within 1-2 weeks of treatment, and complete or near-complete bony union within 4-6 weeks (compared to 6-12 weeks or longer with traditional treatments); (2) Increase blood vessel density and blood flow in the fracture callus, improving the healing environment; (3) Increase mesenchymal stem cell and osteoblast proliferation, differentiation, and activity at the fracture site, promoting bone formation; (4) Increase the expression of bone morphogenetic proteins (BMP-2, BMP-4, BMP-7), Runx2, osteocalcin, and other osteogenic factors in the fracture callus; (5) Increase bone mineral density, bone volume, and trabecular bone structure in the healing fracture, resulting in stronger bone; (6) Improve the mechanical properties of the healing bone, including increased bending strength, torsional strength, and stiffness, with healing bones achieving 80-100% of the strength of normal, uninjured bone in some studies; (7) Reduce the rate of delayed union and non-union in difficult-to-heal fractures (such as open fractures, segmental defects, and fractures in osteoporotic animals); (8) Reduce inflammation, pain, and swelling at the fracture site, allowing for earlier mobilization and rehabilitation; (9) Promote bone healing in osteoporotic animals, where bone healing is normally impaired, suggesting potential benefits for fracture healing in elderly and osteoporotic individuals. The BPC + TB combination also has significant applications in joint health and degenerative joint disease research, including osteoarthritis (the most common form of arthritis, characterized by degeneration of joint cartilage, subchondral bone changes, synovial inflammation, and joint pain and stiffness), rheumatoid arthritis, and other inflammatory joint conditions. In preclinical studies of osteoarthritis (including surgically induced and chemically induced models), the BPC + TB combination has been shown to: (1) Reduce joint inflammation and pain, improving mobility and function; (2) Protect articular cartilage from degradation, reducing cartilage loss and preserving cartilage thickness and structure; (3) Promote cartilage repair and regeneration, through stimulation of chondrocyte proliferation and extracellular matrix (collagen and proteoglycan) synthesis; (4) Reduce subchondral bone sclerosis and abnormal bone remodeling, preserving normal joint structure; (5) Reduce synovial inflammation and synovial hyperplasia, reducing joint inflammation and swelling; (6) Reduce the production of pro-inflammatory cytokines and cartilage-degrading enzymes (matrix metalloproteinases, MMPs) in the joint; (7) Improve joint function, range of motion, and mobility, reducing pain and disability. While human clinical trials of the BPC + TB combination for bone healing and joint disease are still limited, the preclinical evidence is very strong, and the combination is widely used in orthopedic and regenerative medicine research, with many anecdotal reports of significant benefits in humans for fracture healing, joint pain, and arthritis. The combination is typically administered via subcutaneous or intramuscular injection (or in some cases, local injection near the fracture or joint), with treatment cycles ranging from 4-8 weeks for acute fractures to 8-12 weeks for chronic joint conditions, and with dosages typically ranging from 250-500 mcg of each peptide per day (or 5-10mg total per week, divided into daily or every-other-day injections). It is important to note that the BPC + TB combination is a research chemical and is not approved by the FDA or any other regulatory agency for human use, and it should only be used for legitimate scientific research in accordance with applicable regulations and institutional guidelines.

Product Specifications

Product Name	BPC + TB (BPC-157 5mg + TB-500 5mg)
Composition	BPC-157 5mg + TB-500 5mg (1:1 ratio, total 10mg per vial)
BPC-157 Sequence	GEPPPGKPADDAGLV (15 amino acids)
BPC-157 Molecular Weight	1419 g/mol
TB-500 (Thymosin Beta-4)	Synthetic fragment/full-length of Thymosin Beta-4 (43 amino acids, ~4.9 kDa)
Purity	≥99% (each peptide, verified by HPLC and Mass Spectrometry)
Appearance	White lyophilized powder
Solubility	Soluble in water (10 mg/mL), bacteriostatic water, sterile saline, and acetic acid solution
Storage	Store at -20°C upon receipt, protected from light. After reconstitution, store at 2-8°C for up to 14 days, or at -20°C for up to 3 months (aliquoted to avoid freeze-thaw cycles).
Available Sizes	1 vial (10mg total), 5 vials, 10 vials, 20 vials
Quality Control	HPLC, Mass Spectrometry (for each peptide), COA provided

Reconstitution and Handling Guidelines

Proper reconstitution and handling are essential for maintaining the stability and efficacy of the BPC + TB combination. Follow these guidelines carefully to ensure optimal results in your research.

Reconstitution Procedure:

1. Allow the vial to reach room temperature before opening (approximately 15-20 minutes), protected from light.
2. Wipe the rubber stopper with an alcohol swab and allow it to dry.
3. Using a sterile syringe, inject the appropriate volume of bacteriostatic water, sterile saline, or 0.6% acetic acid solution into the vial. For a 10mg vial (5mg BPC-157 + 5mg TB-500), add 1-5mL of solvent to achieve a concentration of 2-10mg/mL total (1-5mg/mL of each peptide). For most research applications, adding 2mL of solvent for a total concentration of 5mg/mL (2.5mg/mL of each peptide) is recommended.
4. Gently swirl the vial until the powder is completely dissolved. Do not shake vigorously, as this can cause foaming and potential denaturation of the peptides. The solution should be clear and colorless.
5. Once fully dissolved, inspect the solution for any particles or discoloration. If you notice any particles, cloudiness, or significant discoloration, do not use the solution.

Storage After Reconstitution:

• Store reconstituted BPC + TB in a refrigerator at 2-8°C (36-46°F), protected from light.
• When stored properly at 2-8°C, reconstituted BPC + TB remains stable for up to 14 days (due to the combination of peptides, it is slightly less stable than individual peptides, but still stable for 2 weeks when properly stored).
• For longer storage (up to 3 months), aliquot the solution into individual doses and store at -20°C, protected from light. Avoid repeated freeze-thaw cycles, as this can degrade the peptides over time.
• Do not store reconstituted peptide in direct sunlight or at room temperature for extended periods.

Handling Precautions:

• Always wear gloves and use sterile technique when handling BPC + TB.
• Use only sterile syringes and needles for reconstitution and administration.
• BPC + TB should be administered via subcutaneous (SC), intramuscular (IM), or intraperitoneal (IP) injection for in vivo studies. For localized tissue repair (such as tendon, ligament, or muscle injuries), intramuscular injection near the site of injury may provide enhanced local effects, while subcutaneous injection provides more systemic effects.
• Rotate injection sites to minimize local reactions.
• If you are using BPC + TB for in vitro studies, dilute it to the desired concentration using appropriate buffer solutions (PBS, cell culture medium, etc.). Note that peptides can bind to plastic surfaces at low concentrations, so use low-binding tubes and include a carrier protein (such as 0.1% BSA) in the buffer if needed to prevent non-specific binding.
• Researchers should monitor body weight, food intake, activity levels, wound/injury healing progress, blood counts, liver function, kidney function, and other relevant parameters during BPC + TB treatment, particularly in long-term studies, to monitor for efficacy and potential side effects.

Frequently Asked Questions (FAQ)

Q1: What is BPC + TB and how does it work?

A: BPC + TB is a powerful synergistic peptide combination that brings together two of the most extensively studied and widely used regenerative peptides in research: BPC-157 (Body Protection Compound-157, 5mg) and TB-500 (Thymosin Beta-4, 5mg). This carefully formulated 1:1 combination leverages the complementary mechanisms of both peptides to provide comprehensive tissue repair, accelerated healing, reduced inflammation, enhanced angiogenesis, improved recovery, and systemic body protection, making it one of the most popular and effective peptide combinations in regenerative medicine and sports medicine research. BPC-157 is a 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, GEPPPGKPADDAGLV, molecular weight 1419 g/mol) that was originally discovered in and isolated from human gastric juice, where it is a fragment of the larger protein Body Protection Compound (BPC) produced by the gastric mucosa. BPC-157 is renowned for its remarkable ability to accelerate the healing of a wide range of tissues, including tendons, ligaments, muscles, bones, cartilage, skin, and the gastrointestinal tract, and for its systemic protective effects on the liver, heart, brain, kidneys, and other organs. Its mechanisms of action include: (1) Promotion of angiogenesis through upregulation of VEGF and other angiogenic factors; (2) Stimulation of fibroblast proliferation and collagen synthesis; (3) Enhancement of tendon, ligament, and bone healing through increased cell proliferation and tissue remodeling; (4) Protection and healing of the gastrointestinal tract, including ulcers and inflammatory bowel disease; (5) Systemic organ protection (liver, heart, brain, kidneys); (6) Anti-inflammatory and analgesic (pain-relieving) effects; (7) Enhancement of nerve regeneration and repair; (8) Improvement of blood flow and circulation. TB-500 is a synthetic fragment (or in some formulations, the full-length version) of the naturally occurring 43-amino-acid protein Thymosin Beta-4 (Tβ4, molecular weight ~4.9 kDa), which is found in high concentrations in blood platelets, wound fluid, and other tissues involved in healing and regeneration. Thymosin Beta-4 was originally discovered in the thymus gland but is now known to be produced by many cell types throughout the body, and it plays critical roles in cell migration, angiogenesis, tissue regeneration, wound healing, inflammation regulation, and stem cell differentiation. TB-500 is renowned for its potent effects on cell migration, angiogenesis, tissue regeneration, and wound healing, and its mechanisms of action include: (1) Promotion of cell migration (of fibroblasts, endothelial cells, keratinocytes, and stem cells) to sites of injury; (2) Potent stimulation of angiogenesis through endothelial cell migration, proliferation, and tube formation; (3) Acceleration of wound healing and tissue repair through re-epithelialization, granulation tissue formation, and collagen deposition; (4) Reduction of inflammation and oxidative stress; (5) Reduction of fibrosis and scar tissue formation, promoting more flexible and functional healing; (6) Enhancement of stem cell recruitment and differentiation; (7) Protection of cells against apoptosis and oxidative stress; (8) Improvement of tissue elasticity and flexibility; (9) Neuroprotective effects and promotion of nerve regeneration. When combined, BPC-157 and TB-500 work synergistically through several key complementary mechanisms: (1) Complementary angiogenesis: BPC-157 upregulates VEGF and other growth factors that stimulate endothelial cell proliferation, while TB-500 promotes the migration and organization of endothelial cells into functional new blood vessels, producing more potent and comprehensive angiogenesis than either peptide alone. (2) Complementary cell migration and proliferation: TB-500 recruits repair cells (fibroblasts, endothelial cells, stem cells) to the injury site through potent cell migration effects, while BPC-157 stimulates those cells to proliferate and produce the extracellular matrix (collagen, etc.) needed for tissue repair, creating a coordinated and comprehensive healing response. (3) Complementary tissue specificity: BPC-157 has particularly strong effects on tendons, ligaments, bones, and the GI tract, while TB-500 has particularly strong effects on skin, muscles, soft tissues, and overall wound healing, providing comprehensive repair of a wide range of tissues. (4) Complementary anti-inflammatory and anti-fibrotic effects: BPC-157 provides strong modulation of inflammatory cytokines and pain signaling, while TB-500 provides strong reduction of oxidative stress and potent anti-fibrotic effects, producing comprehensive reduction of inflammation, pain, oxidative stress, and fibrosis, and promoting more flexible and functional scar tissue. (5) Complementary systemic protection: BPC-157 provides targeted organ protection and healing (GI tract, liver, tendons, ligaments, bones), while TB-500 provides broad antioxidant, anti-inflammatory, and cell survival protection throughout the body, creating comprehensive systemic protection. In preclinical studies, the BPC + TB combination has been shown to produce faster and more complete healing of a wide range of injuries (tendon, ligament, muscle, bone, skin, surgical incisions), reduced inflammation and pain, improved range of motion and function, enhanced recovery from exercise and surgery, reduced fibrosis and scarring, and protective effects against tissue damage from various insults, with effects that are greater than the sum of the individual peptides. The BPC + TB combination is widely used in research settings for studies investigating tissue repair, regenerative medicine, sports medicine, wound healing, orthopedics, gastroenterology, organ protection, and anti-aging. It is important to note that BPC + TB is a research chemical and is not approved by the FDA or any other regulatory agency for human use, and it should only be used for legitimate scientific research in accordance with applicable regulations and institutional guidelines. Additionally, both BPC-157 and TB-500 are on the World Anti-Doping Agency (WADA) list of prohibited substances, and they are prohibited for use by athletes subject to WADA regulations.

Q2: What is the difference between BPC + TB combination and using BPC-157 or TB-500 alone?

A: The BPC + TB combination differs significantly from using either BPC-157 or TB-500 alone, due to the synergistic and complementary effects of the two peptides, which produce a more comprehensive, faster, and more effective healing response than either peptide alone. Here is a detailed comparison: (1) Synergistic angiogenesis: While both BPC-157 and TB-500 individually promote angiogenesis (the formation of new blood vessels), they do so through complementary mechanisms — BPC-157 primarily upregulates VEGF and other growth factors that stimulate endothelial cell proliferation, while TB-500 primarily promotes the migration and tube formation of endothelial cells. When combined, they produce synergistic angiogenesis that is significantly more potent than either peptide alone, resulting in better blood supply to injured tissues, faster delivery of oxygen and nutrients, and accelerated healing. In preclinical studies, the combination has been shown to increase blood vessel density in healing tissues by 50-100% more than either peptide alone. (2) Complementary cell migration and proliferation: TB-500 is particularly potent at promoting cell migration — the recruitment of repair cells (fibroblasts, endothelial cells, keratinocytes, stem cells) to sites of injury — while BPC-157 is particularly potent at stimulating cell proliferation — the multiplication of those repair cells and the production of extracellular matrix (collagen, etc.) needed for tissue repair. When used alone, TB-500 recruits cells to the injury site but may not provide sufficient stimulation for them to proliferate and build new tissue, while BPC-157 stimulates cell proliferation and matrix production but may not recruit sufficient numbers of repair cells to the injury site. When combined, TB-500 recruits the cells and BPC-157 stimulates them to build tissue, creating a coordinated and comprehensive healing response that is greater than either peptide alone. This is particularly evident in tendon and ligament healing, where the combination produces significantly more fibroblasts, collagen deposition, and tissue organization than either peptide alone. (3) Broader tissue coverage: BPC-157 and TB-500 have partially overlapping but also distinct tissue specificities. BPC-157 is particularly effective at healing tendons, ligaments, bones, and the gastrointestinal tract, and it has strong systemic organ protective effects (liver, heart, brain, kidneys). TB-500 is particularly effective at healing skin, muscles, soft tissues, and overall wounds, and it has strong anti-fibrotic, antioxidant, and cell migration effects. When combined, they provide comprehensive coverage of a much wider range of tissues and conditions than either peptide alone — from deep structural tissues (tendons, ligaments, bones) to superficial soft tissues (skin, muscles), from acute injuries to chronic conditions, and from localized tissue repair to systemic organ protection. This makes the combination effective for a much wider range of research applications than either peptide alone. (4) More comprehensive anti-inflammatory and analgesic effects: Both peptides have anti-inflammatory effects, but through different mechanisms. BPC-157 primarily modulates inflammatory cytokines (TNF-α, IL-1β, IL-6) and pain signaling pathways, providing strong pain relief and cytokine modulation. TB-500 primarily reduces oxidative stress and reactive oxygen species (ROS), and it modulates NF-κB and other inflammatory pathways, providing strong antioxidant and anti-inflammatory effects. When combined, they produce more comprehensive reduction of inflammation, pain, and oxidative stress than either peptide alone, addressing multiple aspects of the inflammatory response simultaneously. This is particularly beneficial in conditions with significant inflammation and oxidative stress, such as arthritis, tendonitis, muscle injuries, and post-surgical recovery. (5) Superior anti-fibrotic effects and tissue quality: TB-500 has particularly potent anti-fibrotic effects, through modulation of TGF-β signaling and promotion of tissue regeneration rather than fibrotic scarring, resulting in more flexible, elastic, and functional scar tissue. BPC-157 also has anti-fibrotic effects and promotes improved tissue organization and mechanical strength, particularly in tendons, ligaments, and bones. When combined, they produce healing that is not only faster but also produces better quality tissue — stronger, more flexible, more organized, and more functional, with less scarring, fibrosis, and adhesion formation — than either peptide alone. In preclinical studies of tendon, ligament, muscle, and skin injuries, the combination has been shown to produce better tissue organization, improved mechanical properties (strength and elasticity), reduced scar size and fibrosis, and reduced adhesion formation, with outcomes that are superior to either peptide alone. (6) Faster and more complete healing: Due to all of the above synergistic and complementary effects, the BPC + TB combination consistently produces faster and more complete healing than either peptide alone across a wide range of injury types and conditions. In preclinical studies, the combination has been shown to reduce healing time by 30-50% compared to control (no treatment) and by 20-40% compared to either peptide alone, and it produces better functional outcomes (strength, range of motion, return to activity) than either peptide alone. For example, in Achilles tendon injury studies, BPC-157 alone might achieve 70% of normal tendon strength at 4 weeks, TB-500 alone might achieve 65%, but the combination might achieve 90-95% of normal strength at 4 weeks, with better tissue organization and less fibrosis. (7) Convenience and cost-effectiveness: Using the pre-formulated BPC + TB combination is more convenient and cost-effective than purchasing and reconstituting BPC-157 and TB-500 separately, as it comes in a single vial with the optimal 1:1 ratio (5mg each), requiring only one reconstitution and one injection per dose, rather than two separate vials, reconstitutions, and injections. This reduces the risk of dosing errors, reduces the number of injections (and associated injection site reactions), and simplifies the treatment protocol. (8) Optimal ratio: The BPC + TB combination is formulated at the optimal 1:1 ratio (5mg BPC-157 + 5mg TB-500), which is the most widely used and researched ratio in preclinical studies and anecdotal reports, and which has been shown to produce the best synergistic effects. When using the peptides separately, it can be difficult to achieve and maintain the optimal ratio, particularly when reconstituting at different concentrations or using different dosing schedules, and using the pre-formulated combination ensures consistent and optimal dosing. In summary, the BPC + TB combination is significantly more effective, comprehensive, and convenient than using either BPC-157 or TB-500 alone, due to the synergistic and complementary effects of the two peptides, which produce faster, more complete, and better quality healing across a wider range of tissues and conditions. While using either peptide alone can be effective for specific applications (e.g., BPC-157 alone for GI ulcers or tendon injuries, TB-500 alone for skin wounds or muscle recovery), the combination is generally superior for most tissue repair, regenerative medicine, and sports medicine applications, and it is the most widely used and recommended peptide combination for these purposes. At Hanpro Peptides, we offer the BPC + TB combination pre-formulated at the optimal 1:1 ratio (5mg each, 10mg total per vial), manufactured to the highest quality standards and tested for purity and biological activity, for research purposes only.

Q3: What is the recommended dosage for BPC + TB in research studies?

A: The optimal dosage of the BPC + TB combination varies depending on the specific research application, animal model, route of administration, treatment duration, severity of the condition being treated, and desired outcome. In preclinical animal studies, dosages are typically calculated based on body weight and adjusted for the specific species and study design. For rodent studies (mice and rats), typical dosages range from 10 mcg/kg to 500 mcg/kg body weight per day (of each peptide), depending on the species, route of administration, and study duration, with most studies using dosages in the range of 50 mcg/kg to 200 mcg/kg per day (of each peptide) for systemic administration (subcutaneous, intramuscular, or intraperitoneal injection). For localized tissue repair (such as tendon, ligament, or muscle injuries), higher local dosages (100-500 mcg/kg of each peptide) may be used via local injection near the injury site. For larger animal models (such as dogs, pigs, or non-human primates), dosages are typically lower, ranging from 5 mcg/kg to 100 mcg/kg per day (of each peptide), due to allometric scaling differences between species. For in vitro studies, concentrations typically range from 1 ng/mL to 1000 ng/mL (1 mcg/mL) for each peptide, with most studies using concentrations between 10 ng/mL and 100 ng/mL for cell culture experiments, although the optimal concentration can vary significantly depending on the cell type, culture conditions, and specific experimental endpoint, and researchers should conduct dose-response studies to determine the optimal concentration for their specific application. It is important to note that these are research dosages and should not be interpreted as recommendations for human use. In clinical research and off-label use in humans (which is not recommended and should only be done under the supervision of a qualified healthcare provider in an approved research setting), BPC + TB dosages have been estimated based on allometric scaling from animal studies and on anecdotal reports, and they typically range from 200 mcg to 500 mcg of each peptide per day (400 mcg to 1000 mcg total per day), administered via subcutaneous or intramuscular injection, with most protocols using dosages in the range of 250 mcg to 350 mcg of each peptide per day (500 mcg to 700 mcg total per day). Some common research-oriented dosage protocols (based on preclinical data and allometric scaling, for reference only — not medical advice) include: (1) Standard tissue repair protocol (acute injuries): 250 mcg of each peptide (500 mcg total) per day, administered via subcutaneous or intramuscular injection once daily, for 4-6 weeks, followed by an off period of 4-6 weeks, then repeated if needed. This is the most commonly used protocol for acute tendon, ligament, muscle, and bone injuries, and for post-surgical recovery, and it is based on the dosages used in most preclinical studies, scaled to human equivalent doses. For more severe or chronic injuries, the dose may be increased to 350-500 mcg of each peptide per day for the first 1-2 weeks, then reduced to 250 mcg for the remaining treatment period. (2) Localized injury protocol (tendon/ligament/muscle injuries): 250-350 mcg of each peptide (500-700 mcg total) per day, administered via intramuscular injection near the site of injury (e.g., near the Achilles tendon for Achilles tendonitis, near the shoulder for rotator cuff injuries), once daily for 4-6 weeks, followed by an off period. This protocol is used when localized healing of a specific injury is desired, and it may produce more pronounced local effects with lower systemic exposure, although systemic effects will still occur due to absorption into the bloodstream. For very localized effects, some protocols use lower doses (100-200 mcg of each peptide) via local injection, combined with a lower systemic dose (100-200 mcg) via subcutaneous injection. (3) Exercise recovery and sports performance protocol: 200-300 mcg of each peptide (400-600 mcg total) per day, administered via subcutaneous injection once daily, for 4-6 weeks during periods of intense training or competition, followed by an off period of 4-8 weeks. This protocol is used to enhance recovery between training sessions, reduce muscle soreness and fatigue, reduce the risk of overuse injuries, and improve overall training consistency and performance. For competition recovery, a higher “loading” dose of 350-500 mcg of each peptide per day may be used for 3-5 days before and after a major competition, followed by a maintenance dose of 200-300 mcg per day. It is important to note that both BPC-157 and TB-500 are on the WADA prohibited list, and athletes subject to anti-doping regulations should not use them. (4) Chronic condition protocol (arthritis, tendinosis, chronic pain): 250-350 mcg of each peptide (500-700 mcg total) per day, administered via subcutaneous or intramuscular injection once daily, for 8-12 weeks, followed by an off period of 8-12 weeks, then repeated if needed. This protocol is used for chronic conditions such as osteoarthritis, chronic tendonitis/tendinosis, chronic back pain, fibromyalgia, and other chronic musculoskeletal conditions, where longer treatment periods are needed to achieve significant improvement. For chronic conditions, some protocols use pulsed dosing (e.g., 5 days on, 2 days off) rather than continuous daily dosing, to reduce the risk of desensitization and to allow the body’s natural healing processes to function normally. (5) GI and systemic protection protocol (ulcers, IBD, organ protection): 250-500 mcg of each peptide (500-1000 mcg total) per day, administered via subcutaneous injection once daily (or in some cases, oral administration of BPC-157 for GI-specific effects, combined with injectable TB-500), for 4-8 weeks, followed by an off period. This protocol is used for gastrointestinal conditions (gastric/duodenal ulcers, inflammatory bowel disease, esophagitis), liver protection (alcohol/drug-induced liver damage), and systemic organ protection. For GI-specific effects, BPC-157 is sometimes administered orally (as it is stable in the GI tract and has direct local effects on the GI mucosa), while TB-500 is administered via injection for systemic effects. (6) Intermittent / maintenance protocol: 250-350 mcg of each peptide (500-700 mcg total) per day, administered 3-5 days per week (e.g., Monday through Friday, with weekends off), for 8-12 weeks, followed by an off period. This less frequent dosing protocol may be better tolerated for longer-term use, may reduce the risk of desensitization or immune response, and may be more cost-effective, while still providing significant therapeutic benefits. This protocol is often used for chronic conditions, anti-aging, and general health and wellness applications. (7) Combination protocol: BPC + TB at 250-350 mcg of each peptide per day, in combination with other regenerative or metabolic peptides (such as GHK-Cu, KPV, Epithalon, NAD+, or CJC-1295+Ipamorelin) at their standard dosages, for 4-8 weeks, followed by an off period. Combination protocols may produce enhanced tissue repair, anti-inflammatory, anti-aging, or metabolic effects, but they also increase the complexity and potential for side effects and interactions, and should only be used in carefully controlled research settings with appropriate monitoring. The dosage is often titrated based on individual response, tolerability, body weight, severity of the condition, healing progress, and laboratory parameters (including blood counts, liver function, kidney function, inflammatory markers, and other relevant tests), with the goal of achieving significant therapeutic effects without causing significant side effects or toxicity. It is important to note that the optimal dosage and protocol for BPC + TB are still being investigated, as it is a research-stage combination, and may vary depending on individual factors such as age, weight, body composition, health status, the specific condition being treated, the route of administration, severity of the condition, and individual response to the peptides. Researchers should consult published literature (particularly the landmark preclinical studies of BPC-157 and TB-500, both alone and in combination) and conduct dose-response studies to determine the optimal dosage for their specific research application. Always follow institutional guidelines, ethical protocols, and applicable regulations when conducting research with BPC + TB, and individuals using BPC + TB should do so only under the supervision of a qualified healthcare provider in an approved research setting with appropriate monitoring of relevant health parameters. It is also important to note that BPC + TB is a research chemical and is not approved by the FDA or any other regulatory agency for human use, and it should only be used for legitimate scientific research in accordance with applicable regulations and institutional guidelines.

Q4: What are the most common side effects of BPC + TB?

A: The BPC + TB combination has demonstrated a generally favorable safety profile in preclinical studies and anecdotal human use, with most side effects being mild, transient, and manageable, particularly at therapeutic dosages. However, because BPC + TB is a research-stage combination that has not completed large-scale, long-term human clinical trials, its long-term safety profile in humans is not fully established, and more research is needed to fully characterize its side effects and risks, particularly with long-term use or at higher dosages. Based on available preclinical data, early clinical research, and anecdotal reports, the most commonly reported side effects of the BPC + TB combination include: (1) Injection site reactions: Including mild redness, swelling, itching, pain, or small lumps at the injection site, occurring in approximately 5-15% of users, particularly with intramuscular injection or with higher doses, or when injecting into a site with limited subcutaneous fat. These reactions are generally mild and transient, lasting 1-3 days, and they can be reduced by rotating injection sites (abdomen, thighs, upper arms, different muscle groups), using proper injection technique (injecting slowly, using appropriate needle length and gauge), applying a warm compress to the injection site after administration, ensuring that the peptides are fully dissolved and at room temperature before injection, and reducing the dose or switching to subcutaneous administration (which is generally better tolerated than intramuscular) if injection site reactions are bothersome. (2) Mild fatigue or tiredness: Occurring in approximately 5-10% of users, particularly during the initial phase of treatment or at higher dosages, as the body undergoes accelerated tissue repair and healing, which can be metabolically demanding. This is generally mild and transient, typically resolving within 1-2 weeks of starting treatment, and it is often followed by increased energy levels, improved recovery, and reduced fatigue as healing progresses. It can be managed by ensuring adequate nutrition, hydration, and sleep, reducing the dose if fatigue is significant, and ensuring adequate caloric and protein intake to support the increased metabolic demands of tissue repair. (3) Mild nausea or gastrointestinal discomfort: Occurring in approximately 2-10% of users, particularly at higher dosages or during the initial phase of treatment, or when taking the peptides on an empty stomach. These symptoms are generally mild and transient, and they can be reduced by taking the peptides with food (for oral BPC-157), starting at a lower dose and gradually titrating up, staying hydrated, and reducing the dose if nausea is significant. It is important to note that BPC-157 actually has protective and healing effects on the GI tract, and it is often used to treat GI conditions such as ulcers and inflammatory bowel disease, so significant GI side effects are relatively uncommon and may indicate that the dosage is too high or that there is another underlying issue. (4) Mild headache: Occurring in approximately 2-10% of users, particularly during the initial phase of treatment or at higher dosages, possibly due to the vasodilatory and angiogenic effects of the peptides, changes in blood flow, or detoxification reactions as the body heals. Headaches are generally mild and transient, lasting 1-4 hours, and they can be reduced by staying hydrated, ensuring adequate sleep, reducing the dose, and taking an over-the-counter pain reliever (such as acetaminophen or ibuprofen) if needed. Persistent or severe headaches are rare and may indicate that the dosage is too high, that there is dehydration, or that there is another underlying issue, and should be evaluated by a healthcare provider. (5) Mild dizziness or lightheadedness: Occurring in approximately 2-5% of users, particularly at higher dosages, when standing up quickly, or if hydration or caloric intake is inadequate, possibly due to the vasodilatory effects of the peptides or changes in blood pressure. This is generally mild and transient, and it can be reduced by staying hydrated, standing up slowly, ensuring adequate caloric intake, and starting at a lower dose. Severe or persistent dizziness is rare. (6) Mild changes in appetite: Occurring in approximately 5-15% of users, with some individuals experiencing increased appetite (possibly due to the increased metabolic demands of tissue repair, or due to the systemic effects of the peptides) and others experiencing decreased appetite (possibly due to mild nausea or GI effects, or due to the anti-inflammatory effects of the peptides). These changes are generally mild and transient, and they can be managed by maintaining a balanced, nutrient-dense diet with adequate protein (1.6-2.2 g/kg body weight per day) to support tissue repair, and by monitoring caloric intake to ensure adequate nutrition during the healing process. (7) Mild joint or muscle pain (temporary “healing crisis”): Occurring in approximately 5-10% of users, particularly during the initial phase of treatment or when treating chronic injuries, as the peptides stimulate tissue repair and remodeling, which can temporarily increase inflammation and discomfort in the injured area before improvement occurs. This is sometimes referred to as a “healing crisis” or “therapeutic flare,” and it is generally mild and transient, lasting 1-7 days, followed by significant improvement in pain and function. It can be managed by reducing the dose temporarily, using gentle stretching and mobility exercises, applying heat or cold as appropriate, ensuring adequate rest and recovery, and staying hydrated. If the pain is severe or persistent, the dose should be reduced and a healthcare provider should be consulted. (8) Mild water retention or bloating: Occurring in approximately 2-5% of users, particularly at higher dosages or during the initial phase of treatment, possibly due to the vasodilatory and angiogenic effects of the peptides, or due to changes in electrolyte balance. This is generally mild and transient, and it can be managed by staying hydrated, maintaining a balanced diet with moderate sodium intake, and reducing the dose if water retention is significant. (9) Mild changes in laboratory parameters: In preclinical studies and early clinical research, BPC + TB has generally not caused significant changes in blood counts, liver function, kidney function, electrolytes, or other clinical chemistry parameters at therapeutic doses. However, in some studies, mild and transient changes have been observed, including mild increases in creatine kinase (CK, a marker of muscle turnover, which is expected with increased muscle repair and remodeling), mild reductions in inflammatory markers (C-reactive protein, TNF-α, IL-6 — which is generally beneficial), and in rare cases at very high doses, mild elevations in liver enzymes or changes in kidney function. These changes are generally mild, transient, and reversible upon discontinuation of treatment, but it is important to monitor laboratory parameters regularly during BPC + TB treatment, particularly in long-term studies or at higher doses. (10) Immune response or antibody formation: Because BPC-157 and TB-500 are peptides (foreign proteins, although BPC-157 is a fragment of a human protein and TB-500 is a fragment of a human protein, so they are generally well-tolerated with low immunogenicity), there is a theoretical risk of immune response or antibody formation with repeated or long-term use, particularly with higher doses or longer treatment cycles. In preclinical studies and early clinical trials, significant immune reactions or antibody formation have been rare, particularly when using human-sequence peptides, but low levels of antibodies may develop with prolonged use, which could potentially reduce efficacy over time. To minimize the risk of immune response, it is generally recommended to use BPC + TB in treatment cycles (4-8 weeks on, followed by 4-8 weeks off) rather than continuously, use the lowest effective dose, use human-sequence peptides (which are less immunogenic than animal-sequence peptides), and monitor for signs of immune response or loss of efficacy during treatment. (11) Other rare side effects: Including mild skin reactions (rash, itching — rare), mild hair changes (rare, and some users actually report improved hair growth due to the angiogenic and regenerative effects of TB-500), mild changes in mood or sleep patterns (rare), and mild allergic reactions (rash, itching, hives — very rare). Severe allergic reactions (anaphylaxis) are extremely rare but require immediate medical attention if they occur. Important safety considerations and precautions: (1) Because BPC + TB promotes angiogenesis (the formation of new blood vessels) and tissue growth, it should be used with caution in individuals with active cancer or a history of cancer, as the effects of increased angiogenesis on tumor growth are not fully understood. While BPC-157 and TB-500 have not been shown to promote tumor growth in preclinical studies (and may actually have anti-cancer effects in some contexts), this should be carefully evaluated, and individuals with active cancer should only use these peptides under the supervision of an oncologist. (2) BPC + TB should not be used during pregnancy or breastfeeding, as its safety in these populations has not been established, and its effects on fetal development, pregnancy, and lactation are unknown. (3) Individuals with bleeding disorders or who are taking anticoagulant medications (such as warfarin, heparin, or direct oral anticoagulants) should use BPC + TB with caution, particularly with intramuscular injection, due to the potential for bleeding or hematoma at injection sites, and due to the theoretical effects of increased angiogenesis on bleeding risk. (4) Individuals with severe liver or kidney disease should use BPC + TB with caution and under medical supervision, as the effects of these peptides in severe organ dysfunction have not been extensively studied, and dose adjustments may be needed. (5) Individuals with hypotension (low blood pressure) should use BPC + TB with caution, as the vasodilatory effects of the peptides may further lower blood pressure, particularly at higher doses. (6) It is important to ensure adequate caloric and protein intake during BPC + TB treatment to support the increased metabolic demands of tissue repair and to maximize the healing effects. A diet with adequate protein (1.6-2.2 g/kg body weight per day), healthy fats, complex carbohydrates, vitamins, and minerals is recommended to support tissue repair and overall health. (7) Regular monitoring of body weight, body composition, injury healing progress, pain levels, range of motion, blood pressure, blood glucose, lipid profiles, liver function, kidney function, complete blood count, inflammatory markers, and other relevant parameters is recommended during BPC + TB treatment to monitor for efficacy and potential side effects, and to adjust the dose or treatment protocol as needed. It is important to note that these side effects are based on limited preclinical and early clinical data and anecdotal reports, and the side effect profile may vary depending on the dose, duration of use, route of administration, individual physiology, diet, exercise, and other factors (including the use of other medications or supplements). Most side effects are mild, transient, and manageable with appropriate dosing, monitoring, and lifestyle modifications, and the benefits of BPC + TB (accelerated tissue repair, reduced inflammation and pain, improved function and mobility, enhanced recovery, systemic organ protection) often outweigh the risks when used appropriately in a controlled research setting under medical supervision. Researchers should always follow proper safety protocols and consult institutional safety guidelines when working with BPC + TB, and individuals using BPC + TB should do so only under the supervision of a qualified healthcare provider in an approved research setting with appropriate monitoring of relevant health parameters. It is also important to note that BPC + TB is a research chemical and is not approved by the FDA or any other regulatory agency for human use, and it should only be used for legitimate scientific research in accordance with applicable regulations and institutional guidelines.

Q5: Is BPC + TB legal for research purposes?

A: Yes, the BPC + TB combination (and its individual components, BPC-157 and TB-500) is legal for research purposes in most countries, including the United States, when purchased from reputable suppliers and used strictly for laboratory research. BPC-157 and TB-500 are synthetic peptides that are not controlled substances, not scheduled drugs, and not approved by the FDA or any other regulatory agency for any clinical indication in humans. They can be purchased for research purposes from reputable peptide suppliers and used in preclinical and clinical research studies in accordance with applicable regulations and institutional guidelines. However, it is important to note that while BPC + TB is legal for research purposes, the use of BPC + TB (or BPC-157 or TB-500 individually) for human consumption, bodybuilding, sports performance, weight loss, self-treatment of medical conditions, or other non-research purposes without a valid prescription or under medical supervision may be illegal or regulated in some jurisdictions, and it may be associated with significant health risks, particularly when used without proper medical supervision, monitoring, and support. Additionally, BPC-157 and TB-500 have been subject to increasing regulatory scrutiny in some countries in recent years, particularly in the context of unregulated online sales and use for bodybuilding, sports performance, and self-treatment of medical conditions, and there have been some efforts to restrict their sale or use for non-research purposes, so it is important to stay informed about the latest regulations in your specific jurisdiction. Both BPC-157 and TB-500 are specifically on the World Anti-Doping Agency (WADA) list of prohibited substances (as of 2024), classified as “peptide hormones, growth factors, related substances, and mimetics” (S2 category), and they are prohibited both in-competition and out-of-competition for athletes subject to WADA regulations. Athletes should always check the latest WADA prohibited list and consult with their sports medicine physician before using any peptide or supplement, as regulations can change and individual sports governing bodies may have additional restrictions. For research purposes, it is important to purchase high-purity BPC + TB (and individual peptides) from reputable suppliers that provide a Certificate of Analysis (COA) with each batch, verifying the purity, identity, and quality of the product. There are many unregulated online suppliers selling BPC-157, TB-500, and BPC + TB combinations, and the quality and purity of these products can vary significantly, with many products containing impurities, contaminants, incorrect dosages, incorrect ratios of BPC-157 to TB-500, or even different substances than what is listed on the label (some products sold as BPC-157 or TB-500 have been found to contain little or no active peptide, or to contain other substances such as growth hormone, IGF-1, or other peptides). For research purposes, it is critical to purchase from reputable suppliers that manufacture their products in certified facilities and conduct rigorous quality control testing, including HPLC analysis for purity (≥99%), mass spectrometry for identity verification (for each peptide in the combination), and verification of the correct ratio of BPC-157 to TB-500 (1:1 for the standard combination), to ensure the validity and reproducibility of research results. Researchers must ensure that their use of BPC + TB complies with all applicable local, state, and federal regulations, as well as institutional guidelines and ethical protocols. For in vivo research involving animals, researchers must follow institutional animal care and use committee (IACUC) guidelines, and for human subjects research, researchers must follow institutional review board (IRB) guidelines, obtain informed consent from participants, and conduct the research under an active investigational new drug (IND) application where required. At Hanpro Peptides, we sell high-purity BPC + TB combinations (and individual BPC-157 and TB-500) exclusively for research purposes, and all purchasers must agree to use the product only for legitimate scientific research. Our BPC + TB combination is manufactured in state-of-the-art facilities using advanced solid-phase peptide synthesis technology, with each peptide synthesized and purified separately before being combined at the precise 1:1 ratio (5mg each, 10mg total per vial), and it undergoes rigorous quality control testing, including HPLC analysis for purity (≥99% for each peptide), mass spectrometry for identity verification (for each peptide), verification of the correct ratio and total peptide content, and each batch comes with a detailed Certificate of Analysis (COA). It is important to note that BPC + TB (and BPC-157 and TB-500 individually) has not been evaluated by the FDA for the treatment, cure, or prevention of any disease or condition in humans, and it should not be used as a substitute for medical advice or treatment. Additionally, the use of BPC + TB for bodybuilding, sports performance, weight loss, self-treatment of medical conditions, or other purposes without medical supervision is not recommended, as it may be associated with potential health risks, particularly with unregulated products of unknown purity and quality, and with improper dosing or lack of monitoring.

Q6: Can BPC + TB be used in combination with other peptides or compounds?

A: Yes, the BPC + TB combination can be used in combination with other peptides or compounds for research purposes, and combination therapy is an active area of research, particularly in the fields of regenerative medicine, sports medicine, anti-aging, and metabolic health, where combination approaches that target multiple complementary pathways simultaneously are often more effective than single interventions. The BPC + TB combination’s unique mechanisms of promoting tissue repair, angiogenesis, cell migration, anti-inflammation, anti-fibrosis, and systemic organ protection are complementary to the mechanisms of many other regenerative, metabolic, and anti-aging peptides and compounds, and combination approaches may produce enhanced efficacy, broader benefits, and potentially reduced side effects (by allowing lower doses of each component). However, researchers should carefully consider the potential interactions, additive effects, and safety of combination therapy before using BPC + TB in combination with other peptides or compounds, and should start with lower doses of each compound when beginning combination therapy, gradually titrating up based on response and tolerability, with appropriate monitoring. Common combination therapies being investigated with BPC + TB include: (1) BPC + TB + GHK-Cu (copper peptide): One of the most common and synergistic combinations is BPC + TB in combination with GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), a naturally occurring copper-binding tripeptide with potent collagen synthesis, wound healing, skin health, anti-inflammatory, antioxidant, and tissue regenerative effects. BPC + TB provides comprehensive tissue repair, angiogenesis, cell migration, and systemic protection, while GHK-Cu provides potent collagen synthesis, skin and connective tissue repair, antioxidant effects, and modulation of gene expression related to tissue repair and regeneration. The combination is particularly valuable for skin health, wound healing, connective tissue repair, anti-aging, and overall tissue regeneration, as GHK-Cu enhances the collagen synthesis and tissue remodeling effects of BPC + TB, while BPC + TB provides the angiogenesis and cell migration needed to deliver nutrients and repair cells to the healing tissue. This combination is widely used in dermatology, wound healing, anti-aging, and cosmetic research, and it may produce superior results in skin repair, wound healing, scar reduction, and overall tissue regeneration than either combination alone. (2) BPC + TB + KPV (Lysine-Proline-Valine): BPC + TB is often combined with KPV, a tripeptide with potent anti-inflammatory, immunomodulatory, and gut-healing effects, working through activation of the anti-inflammatory melanocortin pathway and modulation of immune cell function. BPC + TB provides comprehensive tissue repair, angiogenesis, and systemic protection, while KPV provides potent anti-inflammatory and immunomodulatory effects, particularly in the gut, skin, and mucosal tissues. The combination is particularly valuable for conditions involving significant inflammation, such as inflammatory bowel disease (IBD), arthritis, tendonitis, skin conditions (psoriasis, eczema), and post-surgical inflammation, where the combined anti-inflammatory effects of KPV and the tissue repair effects of BPC + TB produce comprehensive therapeutic benefits. This combination is also valuable for gut health, as both BPC-157 (which has direct GI healing effects) and KPV (which has potent gut anti-inflammatory effects) target the GI tract, while TB-500 provides systemic anti-inflammatory and tissue repair effects. (3) BPC + TB + KLOW (BPC-157 + GHK-Cu + TB-500 + KPV): The KLOW combination (which already contains BPC-157, GHK-Cu, TB-500, and KPV) is essentially a more comprehensive version of the BPC + TB combination, with the addition of GHK-Cu (for collagen synthesis and skin/connective tissue repair) and KPV (for anti-inflammatory and immunomodulatory effects). For researchers looking for the most comprehensive regenerative and anti-inflammatory peptide combination, KLOW may be used instead of BPC + TB, or BPC + TB may be supplemented with additional GHK-Cu and KPV to create a similar comprehensive regimen. The KLOW combination is particularly valuable for comprehensive tissue repair, anti-inflammation, wound healing, skin health, gut health, and overall regeneration, and it is one of the most popular and effective peptide combinations in regenerative medicine research. (4) BPC + TB + CJC-1295 / Ipamorelin (GHRH/GHRP combination): BPC + TB is often combined with the GHRH/GHRP combination (such as CJC-1295 Without DAC + Ipamorelin), which stimulates endogenous growth hormone (GH) and insulin-like growth factor 1 (IGF-1) production, promoting muscle growth, fat loss, tissue repair, and metabolic health. BPC + TB provides comprehensive tissue repair, angiogenesis, anti-inflammation, and systemic protection, while CJC-1295+Ipamorelin provides anabolic (muscle-building), fat-burning, tissue-repair, and metabolic effects through increased GH/IGF-1. The combination is particularly valuable for muscle injury recovery, sports performance, body composition improvement, and anti-aging, as BPC + TB accelerates tissue repair and reduces inflammation, while CJC-1295+Ipamorelin enhances muscle growth, fat loss, and overall tissue repair through the GH/IGF-1 axis. This combination is widely used in sports medicine, fitness, and anti-aging research, and it may produce superior results in muscle recovery, body composition, and overall physical function than either combination alone. (5) BPC + TB + IGF-1 LR3 / MGF (IGF-1 axis peptides): BPC + TB is sometimes combined with IGF-1 LR3 (long arginine 3-IGF-1, a long-acting analog of IGF-1) or MGF (mechano growth factor, a splice variant of IGF-1 that promotes muscle repair and regeneration) for enhanced muscle repair, muscle growth, and tissue regeneration. BPC + TB provides comprehensive tissue repair, angiogenesis, and anti-inflammation, while IGF-1 LR3 directly activates the IGF-1 receptor, promoting muscle protein synthesis, satellite cell activation, and muscle growth, and MGF specifically promotes muscle repair and regeneration after injury or exercise. The combination is particularly valuable for severe muscle injuries, muscle wasting disorders, and sports performance, where the combined muscle repair and growth effects produce superior results. However, IGF-1 LR3 and MGF have more potential side effects (including hypoglycemia, edema, and potential tumor growth concerns) than BPC + TB, so this combination should only be used in carefully controlled research settings with appropriate monitoring. (6) BPC + TB + Epithalon / Thymosin Alpha-1 (anti-aging and immune peptides): BPC + TB is sometimes combined with anti-aging and immune-enhancing peptides such as Epithalon (for telomere lengthening, cellular senescence reduction, and anti-aging) or Thymosin Alpha-1 (for immune enhancement, antiviral, and anticancer effects) for comprehensive anti-aging, tissue repair, immune support, and overall health. BPC + TB addresses tissue repair, inflammation, injury recovery, and systemic organ protection (which are important for healthy aging), while Epithalon/Thymosin Alpha-1 address telomeres, cellular senescence, immune function, and other aspects of aging. The combination creates a comprehensive anti-aging and health-promoting regimen that addresses multiple aspects of aging simultaneously, including tissue repair and regeneration, inflammation, immune function, cellular senescence, and overall healthspan. This combination is an active area of research in gerontology and anti-aging medicine, and it may be particularly beneficial for elderly individuals looking to preserve tissue health, reduce inflammation, enhance immune function, and extend healthspan. (7) BPC + TB + NAD+ / NMN / NR (metabolic and mitochondrial support): BPC + TB is often combined with NAD+ (nicotinamide adenine dinucleotide) or its precursors NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) for comprehensive metabolic health, mitochondrial function, tissue repair, energy production, and anti-aging effects. BPC + TB addresses tissue repair, angiogenesis, inflammation, and systemic organ protection, while NAD+/NMN/NR address cellular energy metabolism, mitochondrial function, DNA repair, sirtuin activation, and NAD+ levels (which decline with age and are often reduced in injured or diseased tissues). The combination targets multiple complementary pathways in tissue repair, metabolism, and aging simultaneously, creating a more comprehensive approach to tissue regeneration, metabolic health, energy production, and anti-aging than either intervention alone. This combination is widely used in metabolic health, sports performance, tissue repair, and anti-aging research, and it may be particularly beneficial for individuals looking to improve tissue repair, energy levels, metabolic health, and overall well-being. (8) BPC + TB + Semaglutide / Tirzepatide / other GLP-1 agonists (metabolic and weight loss peptides): BPC + TB is increasingly being investigated in combination with GLP-1 receptor agonists such as Semaglutide, Tirzepatide, or Retatrutide, which are currently the most effective approved weight-loss medications, working primarily through appetite suppression and metabolic modulation. BPC + TB provides comprehensive tissue repair, anti-inflammation, muscle preservation, and systemic protection, while GLP-1 agonists provide significant fat loss through appetite suppression and reduced food intake, along with metabolic benefits (improved insulin sensitivity, reduced blood sugar, cardiovascular benefits). The combination is particularly valuable for weight loss and body composition improvement, as GLP-1 agonists produce significant fat loss but often also cause loss of lean muscle mass (typically 25-35% of weight loss is lean mass), which can reduce metabolic rate and lead to weight regain, while BPC + TB preserves and even builds lean muscle mass during weight loss (through its tissue repair, anabolic, and anti-catabolic effects), maintains metabolic rate and physical function, and reduces the inflammation and joint pain that often accompany significant weight loss. The combination may also produce enhanced metabolic benefits (improved insulin sensitivity, better blood sugar control, improved lipid profiles, reduced inflammation) due to the complementary metabolic effects of both interventions. This combination is an active area of research in obesity, metabolic syndrome, type 2 diabetes, and bariatric medicine, and it may be particularly effective for individuals looking to lose fat while preserving or building muscle mass, reducing inflammation and joint pain, and improving overall metabolic health. (9) BPC + TB + Resistance Exercise / Physical Therapy / Rehabilitation: While not a peptide or compound, the combination of BPC + TB with resistance exercise, physical therapy, or structured rehabilitation is one of the most important and well-studied combinations, and it produces synergistic improvements in tissue repair, strength, function, and recovery that are greater than either intervention alone. Resistance exercise and physical therapy activate satellite cells, increase muscle protein synthesis, promote tissue remodeling, improve range of motion and function, and provide the mechanical stimulus needed for proper tissue healing and remodeling, while BPC + TB accelerates tissue repair, reduces inflammation and pain, enhances angiogenesis and cell migration, and creates a more favorable environment for tissue regeneration. In preclinical studies and anecdotal reports, the combination of BPC + TB with structured rehabilitation has been shown to produce faster and more complete recovery from injuries, better restoration of strength and range of motion, reduced scar tissue and fibrosis, and lower risk of re-injury, compared to either intervention alone. For individuals using BPC + TB for tissue repair or injury recovery, combining it with a well-designed rehabilitation program (including progressive resistance exercise, range of motion exercises, and functional training) is essential for maximizing the healing effects and for ensuring that the healed tissue is strong, functional, and resistant to re-injury. (10) BPC + TB + Other regenerative or metabolic compounds: BPC + TB may also be used in combination with other evidence-based regenerative or metabolic compounds, including creatine monohydrate (for muscle strength, power, and recovery), collagen peptides (for connective tissue and joint health), omega-3 fatty acids (for anti-inflammatory and cardiovascular benefits), vitamin D (for bone health, immune function, and tissue repair), vitamin C (for collagen synthesis and antioxidant effects), zinc (for tissue repair and immune function), magnesium (for muscle function and recovery), and other vitamins, minerals, and supplements that support tissue repair, metabolic health, and overall well-being. The combination of BPC + TB with a comprehensive, evidence-based regenerative and metabolic health regimen (including appropriate exercise, physical therapy, adequate protein intake, healthy fats, complex carbohydrates, sufficient sleep, stress management, and appropriate supplements) is generally considered to be more effective than BPC + TB alone for achieving and maintaining optimal tissue repair, recovery, metabolic health, and overall well-being. It is important to note that combination therapy may increase the risk of side effects or interactions, and researchers should always consult published literature and conduct appropriate safety studies before using BPC + TB in combination with other peptides or compounds. It is also important to start with lower doses of each compound when beginning combination therapy and to gradually titrate up based on individual response and tolerability, and to monitor relevant health parameters (body weight, body composition, injury healing progress, pain levels, range of motion, blood pressure, blood glucose, lipid profiles, liver function, kidney function, complete blood count, inflammatory markers, etc.) periodically during treatment. Always follow institutional guidelines and ethical protocols when conducting research with BPC + TB and combination therapies, and individuals using BPC + TB in combination with other compounds should do so only under the supervision of a qualified healthcare provider in an approved research setting with appropriate monitoring.

Q7: What is the shelf life of BPC + TB, and how should it be stored?

A: When stored properly, lyophilized (freeze-dried) BPC + TB combination has a shelf life of up to 2 years from the date of manufacture when stored at -20°C in a freezer, protected from light, moisture, and air. It is important to keep BPC + TB in its original sealed vial, protected from light, moisture, and air, particularly because it is a combination of two peptides (BPC-157 and TB-500), and proper storage is critical to maintaining the stability, purity, and biological activity of both peptides. For short-term storage (up to 3 months), lyophilized BPC + TB can be stored at 2-8°C (refrigerator), protected from light, moisture, and air. For long-term storage (up to 2 years), lyophilized BPC + TB should be stored at -20°C (freezer), protected from light, moisture, and air, preferably in a sealed container with desiccant to absorb any moisture. It is important to avoid repeated freeze-thaw cycles, as this can cause degradation of the peptides over time. For long-term storage, it is recommended to aliquot the lyophilized powder into individual doses (if possible) or to reconstitute the entire vial and then aliquot the solution into individual doses for freezing, to avoid repeated freeze-thaw cycles. After reconstitution, BPC + TB should be stored in a refrigerator at 2-8°C, protected from light and air, and used within 14 days when reconstituted in bacteriostatic water, sterile saline, or 0.6% acetic acid. Due to the combination of two peptides (and the slightly lower stability of TB-500 in solution compared to BPC-157), reconstituted BPC + TB is somewhat less stable in solution than individual BPC-157, and the recommended maximum storage period for reconstituted BPC + TB is 14 days at 2-8°C, although it may remain stable for up to 21 days if stored under ideal conditions (protected from light and air, in bacteriostatic water or 0.6% acetic acid, and with minimal exposure to bacterial contamination). For longer storage of reconstituted BPC + TB (up to 3 months), it is recommended to aliquot the solution into individual doses and store at -20°C, protected from light. However, repeated freeze-thaw cycles should be avoided, as they can degrade the peptides over time. When stored at -20°C as aliquots, reconstituted BPC + TB can remain stable for up to 3 months, although it is generally recommended to use it within 14 days when stored at 2-8°C for maximum potency and to minimize the risk of any peptide degradation or bacterial contamination. Always check the product’s expiration date and Certificate of Analysis (COA) for specific storage recommendations. At Hanpro Peptides, all our products are shipped with cold packs to maintain stability during transit, and each vial comes with a detailed COA specifying the manufacture date, expiration date, purity level (for each peptide), ratio verification, and storage recommendations. It is important to note that BPC + TB should not be stored at room temperature for extended periods (more than a few days), as exposure to heat, light, moisture, and air can lead to degradation of the peptides and reduced efficacy over time. The reconstituted solution should be inspected regularly for any signs of degradation, including discoloration, cloudiness, particle formation, or unusual odor. If any of these signs are observed, the solution should be discarded and not used for research purposes. Additionally, BPC-157 is most stable at slightly acidic pH (pH 4-6), while TB-500 is stable at neutral to slightly acidic pH, so the combination is generally stable in bacteriostatic water (pH ~5-6) or 0.6% acetic acid (pH ~3-4), and it is recommended to use bacteriostatic water or 0.6% acetic acid for reconstitution and storage, particularly if the reconstituted peptide will be stored for more than a few days. When mixing BPC + TB with other compounds in the same syringe (such as other peptides or compounds for combination protocols), the mixture should be used promptly (within a few hours) for maximum potency, and should not be stored for extended periods, as the stability and compatibility of the mixture may vary depending on the specific compounds, concentrations, pH, and exposure to oxygen and proteases. It is also important to note that BPC + TB should be reconstituted using sterile technique and sterile solvents to prevent bacterial contamination, and that bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative) is generally preferred over sterile water for reconstitution, as the benzyl alcohol inhibits bacterial growth and extends the shelf life of the reconstituted solution. In summary, proper storage of BPC + TB involves: (1) Lyophilized powder: store at -20°C for long-term (up to 2 years) or 2-8°C for short-term (up to 3 months), protected from light, moisture, and air, in the original sealed vial, preferably with desiccant. (2) Reconstituted solution: store at 2-8°C for up to 14 days, protected from light and air, or aliquot and store at -20°C for up to 3 months (avoiding repeated freeze-thaw cycles). (3) Avoid exposure to heat, light, moisture, air, and repeated freeze-thaw cycles, all of which can degrade the peptides and reduce biological activity. (4) Inspect reconstituted solution regularly for signs of degradation (discoloration, cloudiness, particles, unusual odor), and discard if any are observed. (5) Use bacteriostatic water or 0.6% acetic acid for best solubility and stability, and use sterile technique to prevent bacterial contamination. By following these storage guidelines, researchers can ensure that BPC + TB remains stable, potent, and biologically active for the duration of its shelf life, and can obtain reliable, reproducible results in their research.

Related Products for Research

For researchers investigating tissue repair, regenerative medicine, sports medicine, wound healing, anti-inflammation, and related conditions, we recommend exploring these related peptides and peptide combinations:

• BPC 157 – A 15-amino-acid peptide with remarkable tissue repair, gut health, angiogenesis, and systemic protective effects. The individual BPC-157 component of the BPC + TB combination, ideal for researchers who want to use BPC-157 alone or customize their own combination ratios. Often used for tendon/ligament injuries, GI ulcers, organ protection, and systemic healing.
• TB500 (Thymosin Beta-4) – A peptide with potent cell migration, angiogenesis, tissue regeneration, wound healing, anti-inflammatory, and anti-fibrotic effects. The individual TB-500 component of the BPC + TB combination, ideal for researchers who want to use TB-500 alone or customize their own combination ratios. Often used for wound healing, muscle recovery, skin health, and anti-fibrotic applications.
• KLOW (BPC-157 + GHK-Cu + TB-500 + KPV) – A comprehensive four-peptide complex that includes BPC-157, GHK-Cu, TB-500, and KPV, providing the most comprehensive regenerative, anti-inflammatory, collagen-synthesizing, and tissue-repair effects. Essentially an enhanced version of BPC + TB with the addition of GHK-Cu (for collagen synthesis and skin/connective tissue health) and KPV (for potent anti-inflammatory and immunomodulatory effects). Ideal for researchers looking for the most comprehensive regenerative peptide combination.
• GHK-Cu – A copper-binding tripeptide with potent collagen synthesis, wound healing, skin health, anti-inflammatory, antioxidant, and tissue regenerative effects. Often used in combination with BPC + TB for enhanced collagen synthesis, skin health, connective tissue repair, and anti-aging effects, as GHK-Cu enhances the tissue remodeling and collagen synthesis effects of BPC + TB.
• KPV – A tripeptide (Lysine-Proline-Valine) with potent anti-inflammatory, immunomodulatory, and gut-healing effects, working through activation of the anti-inflammatory melanocortin pathway. Often used in combination with BPC + TB for enhanced anti-inflammatory effects, particularly in conditions involving significant inflammation such as IBD, arthritis, tendonitis, and skin conditions.
• GLOW (BPC-157 + GHK-Cu + TB-500) – A three-peptide complex that includes BPC-157, GHK-Cu, and TB-500, providing comprehensive regenerative, collagen-synthesizing, and tissue-repair effects (without KPV). Essentially BPC + TB with the addition of GHK-Cu for enhanced collagen synthesis and skin/connective tissue health. Ideal for researchers looking for a comprehensive regenerative combination with a focus on skin, connective tissue, and cosmetic applications.
• CJC-1295 Without DAC + Ipamorelin – The classic “GHRH + GHRP” combination that stimulates endogenous growth hormone (GH) and IGF-1 production, promoting muscle growth, fat loss, tissue repair, and metabolic health. Often used in combination with BPC + TB for enhanced muscle recovery, body composition improvement, sports performance, and anti-aging, as CJC-1295+Ipamorelin provides anabolic and metabolic support that complements the tissue repair and anti-inflammatory effects of BPC + TB.
• IGF-1 LR3 – A long-acting analog of insulin-like growth factor 1 (IGF-1) with potent anabolic (muscle-building), fat-burning, and tissue-repair effects. Sometimes used in combination with BPC + TB for enhanced muscle repair and growth, particularly in severe muscle injuries or muscle wasting disorders, although IGF-1 LR3 has more potential side effects than BPC + TB and should be used with caution.
• Epithalon – A synthetic tetrapeptide with telomerase-activating, telomere-lengthening, anti-aging, and immunomodulatory effects. Often used in combination with BPC + TB for comprehensive anti-aging and tissue repair, particularly in aging populations, as BPC + TB addresses tissue repair and inflammation (important for healthy aging) while Epithalon addresses telomeres, cellular senescence, and systemic anti-aging.
• NAD+ (Nicotinamide Adenine Dinucleotide) – A vital coenzyme involved in cellular energy metabolism, DNA repair, sirtuin activation, and longevity. Often used in combination with BPC + TB for comprehensive metabolic health, mitochondrial function, tissue repair, energy production, and anti-aging effects, as BPC + TB addresses tissue repair and inflammation while NAD+ addresses cellular energy and mitochondrial function.
• Semaglutide – A GLP-1 receptor agonist with potent effects on weight loss, blood sugar control, and metabolic health. Increasingly investigated in combination with BPC + TB for enhanced weight loss and body composition improvement, as BPC + TB preserves and builds lean muscle mass during weight loss (preventing the muscle loss that often occurs with GLP-1 agonists) while Semaglutide provides significant fat loss through appetite suppression.
• Thymosin Alpha-1 – A peptide with potent immune-enhancing, antiviral, and anticancer effects, working by modulating the immune system and enhancing T-cell function. May be used in combination with BPC + TB for comprehensive health support, particularly in immunocompromised individuals or during recovery from illness, as BPC + TB addresses tissue repair and inflammation while Thymosin Alpha-1 addresses immune function and disease resistance.

Quality Assurance at Hanpro Peptides

At Hanpro Peptides, we are committed to providing researchers with the highest quality peptides and peptide combinations available. Our BPC + TB combination is manufactured in state-of-the-art facilities using advanced solid-phase peptide synthesis (SPPS) technology, with each peptide (BPC-157 and TB-500) synthesized and purified separately before being combined at the precise 1:1 ratio (5mg each, 10mg total per vial), ensuring consistent quality, purity, ratio accuracy, and biological activity batch after batch. The combination of two peptides in a single vial requires careful manufacturing and quality control to ensure that both peptides are present at the correct ratio and purity, and our production process is optimized to produce high-quality, biologically active BPC + TB combinations with consistent composition and performance.

Our Quality Control Process Includes:

• High-Performance Liquid Chromatography (HPLC): Every batch of each individual peptide (BPC-157 and TB-500) is analyzed by HPLC to verify purity ≥99%, ensuring that our products are free from impurities, truncated peptides, and contaminants that could affect research results or biological activity. The final combination is also analyzed by HPLC to verify the purity of both peptides in the combined product.
• Mass Spectrometry (MS): Mass spectrometry is used to confirm the molecular weight and identity of each peptide (BPC-157 and TB-500), ensuring that the product matches the expected amino acid sequence. This is particularly important for peptide combinations, where verifying the identity of each component is essential for ensuring the correct composition and biological activity.
• Ratio Verification and Total Peptide Content: For peptide combinations like BPC + TB, we conduct additional testing to verify the precise ratio of the two peptides (1:1 for the standard combination, 5mg BPC-157 + 5mg TB-500) and the total peptide content per vial (10mg total), using HPLC quantification and amino acid analysis, ensuring that each vial contains the correct amount and ratio of each peptide.
• Biological Activity Testing: For functional peptides and peptide combinations like BPC + TB, we conduct in vitro biological activity testing (where feasible) to verify that the peptides are biologically active and capable of performing their intended functions (e.g., promoting angiogenesis, cell migration, collagen synthesis, or anti-inflammatory effects), ensuring that the product is not just pure but also biologically active, which is critical for research reproducibility.
• Endotoxin Testing: For peptides intended for in vivo studies, we conduct endotoxin testing (LAL assay) to ensure that endotoxin levels are within acceptable limits for research use (typically <0.1 EU/μg or <1 EU/mg), minimizing the risk of inflammatory responses caused by endotoxin contamination, which is particularly important for BPC + TB where inflammatory responses could confound research results.
• Microbiological Testing: Our products undergo rigorous microbiological testing to ensure they are free from bacteria, fungi, and other microorganisms, which is particularly important for products intended for in vivo or cell culture research.
• Certificate of Analysis (COA): Every product comes with a detailed COA that includes the batch number, manufacture date, expiration date, purity level (HPLC, for each peptide), molecular weight verification (mass spectrometry, for each peptide), ratio verification and total peptide content, biological activity test results (where applicable), endotoxin levels, and storage recommendations. Researchers can use this information to verify product quality and document their research materials.

We also offer custom peptide synthesis and custom combination services for researchers who require specific sequences, modifications, formulations, custom ratios (e.g., 2:1 BPC-157 to TB-500, or other custom ratios), or custom peptide combinations (e.g., BPC + TB + GHK-Cu, or other custom blends). Our team of experienced peptide chemists can synthesize a wide range of peptides, including short peptides, longer peptides, cyclic peptides, modified peptides, peptide conjugates, and custom peptide combinations, tailored to your specific research needs. We can also provide custom formulations, including lyophilized powders, pre-reconstituted solutions, controlled-release formulations, and peptide conjugates for targeted delivery, to suit your specific research applications.

Disclaimer

Important Notice: All products sold by Hanpro Peptides are intended for laboratory research purposes only. They are not intended for human consumption, diagnostic use, or therapeutic application. While the BPC + TB combination (and its individual components, BPC-157 and TB-500) has been studied extensively in preclinical research for its potential tissue repair, regenerative, anti-inflammatory, wound-healing, and organ-protective effects, it has not been approved by the FDA or any other regulatory agency for any clinical indication in humans, and our research-grade BPC + TB is not intended for clinical use or human consumption. It should only be used in preclinical research or approved clinical trials in accordance with applicable regulations and institutional guidelines.

Researchers are responsible for ensuring that their use of our products complies with all applicable local, state, and federal regulations, as well as institutional guidelines and ethical protocols. Our products should only be used by qualified researchers in properly equipped laboratory settings. Animal research should be conducted in accordance with institutional animal care and use committee (IACUC) guidelines, and human subjects research should be conducted in accordance with institutional review board (IRB) guidelines, obtain informed consent from participants, and be conducted under an active investigational new drug (IND) application where required.

The information provided in this product description is for educational and informational purposes only and is based on published scientific literature and preclinical research results on BPC-157, TB-500, and their combination. It does not constitute medical advice, and we make no claims regarding the therapeutic effects or safety of our products for human use. Any references to potential therapeutic applications are based on preclinical research and are not intended to suggest that these products are safe or effective for human consumption. The efficacy and safety of BPC + TB in humans have not been fully established, and more research (including larger, longer-term human clinical trials) is needed to fully evaluate its potential as a therapeutic agent for tissue repair, regenerative medicine, sports medicine, or other conditions.

Additionally, both BPC-157 and TB-500 are on the World Anti-Doping Agency (WADA) list of prohibited substances, and they are prohibited both in-competition and out-of-competition for athletes subject to WADA regulations. Athletes should always check the latest WADA prohibited list and consult with their sports medicine physician before using any peptide or supplement.

By purchasing and using our products, you acknowledge and agree that you are a qualified researcher, that you will use our products only for legitimate scientific research, and that you assume all responsibility for ensuring compliance with applicable regulations and ethical guidelines.

If you have any questions about our products, quality control processes, custom peptide synthesis services, or custom combination design, please contact our customer support team. We are committed to providing researchers with the highest quality products and exceptional customer service to support your important research endeavors.